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Summary 
Inhibition of Toll-like receptor 2 with a monoclonal antibody 
Over the last 2 decades, Toll-like receptors (TLRs) have emerged as critical first-line 
pattern recognition receptors for pathogen detection following microbial infections. In 
addition, they participate in responding to a variety of tissue damage-derived 
endogenous molecules. In both processes, TLRs initiate cellular immune responses. 
Evolutionarily TLRs constitute a rapid and efficient mechanism to stimulate the 
immune system through secreted inflammatory cytokines, leading to the phagocytosis 
of invading microbes or the endocytosis of damaged tissue. TLRs are further essential 
in developing adaptive immunity. Occasionally, however, the activation of TLRs can 
also result in severe diseases. This happens in situations where control over the release 
of pro-inflammatory mediators is lost. Examples include the septic shock pathology due 
to hyperactivation of immune cells following acute infection with bacteria, and chronic 
inflammation sustained by a cycle of endogenous ligand release, inflammatory cytokine 
production and cell necrosis. These and related diseases can effectively be treated by 
antagonistic drugs that inhibit the TLR-based pro-inflammatory response. 
The monoclonal antibody OPN-305, an efficient inhibitor of TLR2, has successfully 
been used to treat septic shock, rheumatoid arthritis and ischemia/reperfusion injury in 
mice. However, whereas the efficacy of the antibody was well established, its molecular 
mechanism remained unexplained. 
In this thesis, the complex between the extracellular domain of murine TLR2 and the 
fragment antigen-binding (Fab) domain of OPN-305 was generated and purified. A first 
structural description of this complex was achieved by negative stain electron 
microscopy (EM) at a resolution of ~22 Å. The three-dimensional reconstruction reveals 
that the antibody binds laterally to the central region of TLR2. Computational mapping 
of crystal structures of both TLR2 and an antibody Fab fragment into the EM-derived 
molecular envelope further identified the TLR1/TLR6 dimerization interface of TLR2 
as the antibody interaction area. The docking experiments indicate that the leucine rich 
repeats (LRRs) 11 to 14 are involved in the protein-protein interaction allowing ten 
amino acids on the surface of TLR2 to be identified as constituting the probable, highly 
discontinuous epitope. 
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These results immediately suggest the mechanism of TLR2 inhibition and the 
antagonistic property of OPN-305 to derive from its ability to block the hetero-
dimerization of TLR2 resulting in silencing of downstream signaling cascades. 
Despite the wealth of information provided by the TLR2/OPN-305 complex structure, 
the precise determination of molecular conformations, exact atomic coordinates and the 
details of interaction await further characterization by techniques such as X-ray 
crystallography. Although the crystal structure of TLR2/OPN-305 could not be solved 
as part of this thesis, the complex was successfully crystallized, with crystals diffracting 
to a maximal resolution of 8 Å. This constitutes a first important step for further efforts 
to solve the crystal structure of TLR2/OPN-305. 
 
Producing mouse/human Toll-like receptors 2 and 6 in insect cells 
using the baculovirus expression system 
TLRs, like most mammalian proteins, require expression systems evolutionarily closely 
related to the organism they originate from rather than traditional prokaryotic 
expression systems such as E. coli. The baculovirus expression system in insect cells is 
a well established technique to produce eukaryotic proteins. However, the low overall 
yield of protein and its purification remain bottlenecks during the procedure. In this 
work recombinant constructs for the expression of murine and human TLR2 and TLR6 
have been designed comprising new secretion peptides and more efficient purification 
tags, providing protein for use in structural studies. Although cloning of recombinant 
baculovirus was successful and protocols for the virus production and protein 
purification were established, only TLR2 was produced in suitable amounts, and an 
increase in the overall protein yield was not achieved. Moreover, the additional Fc 
purification tag proved recalcitrant to enzymatic cleavage. The results of this thesis can 
support further optimization of the protein constructs. 
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I Introduction 
Higher organisms are continuously in contact with their direct environment, depending 
on it for sustenance but also under the constant threat of attack. Invading 
microorganisms including bacteria, viruses and parasites disrupt cellular homeostasis 
and lead to disease. Recognizing and eliminating invading pathogens rapidly is thus 
crucial. A large array of defense strategies has evolved collectively constituting the 
mammalian innate and adaptive immune systems. A first line of host defense against 
invading pathogens is the evolutionary conserved innate immune system that mediates 
the contact to microbial species via phagocytes including macrophages and dendritic 
cells (Akira et al., 2006). This is achieved by a limited number of membrane-associated 
pattern-recognition receptors (PRRs) eliciting an immune response of the organism. 
These receptors are essential to initiate and maintain an antipathogenic response while 
the more specific adaptive immune response develops (McCartney and Colonna, 2009). 
This elaborated system, however, can occasionally lead to auto-immune and 
inflammatory diseases, inter alia when PRR driven signaling pathways are disregulated. 
Using antagonists such as therapeutic antibodies represents a possible strategy to inhibit 
hyperactivated PRRs and has become a major research focus (Hennessy et al., 2010). 
First antagonistic drugs are close to product maturity while many more are in clinical 
trials (Aikawa et al., 2012; Farrar et al., 2011; Hennessy et al., 2010). Understanding the 
molecular principles of pathogen recognition by PRRs and their inhibition by medical 
drugs provides an important contribution to the development of new and the 
improvement of available drugs. 
 
IA Inhibition of TLR2 with a monoclonal antibody 
IA.1 The adaptive and innate immune system 
Adaptive immunity derives from the development of a diverse repertoire of antigen 
receptors by T- and B-cells through gene rearrangement processes. Referred to as 
somatic hypermutation (Diaz and Flajnik, 1998) and V(D)J recombination (Jung and 
Alt, 2004), these processes are critical for the development of immunological memory 
(Akira, 2009). B-cells are part of the humoral immune response and generate highly 
specific antibodies. The T-cell receptors (TCRs), by contrast, are critical in cell-
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mediated immunity (Figure  IA-1). Antibodies and TCRs recognize specific antigens 
that either block infection or flags infected cells for destruction (McCartney and 
Colonna, 2009). 
 
 
Figure  IA-1 The innate and adaptive immune system 
Dendritic cells, macrophages and other immune cells are involved in the activation of the innate and 
adaptive immune response. PRRs like Toll-like receptors link microbial signals to specific gene 
expression programs, which triggers the release of interferons and inflammatory cytokines. This induces 
the inflammatory response of the organism, and can in rare cases lead to autoimmunity reactions. 
Dendritic cells are antigen presenting cells and activate T cells through antigen expression on major 
histocompatibility complex (MHC) class II molecules on their surface. This in turn induces the 
proliferation of T helper cells (Th1 and Th2), the activation of cytotoxic T cells and B cells and the 
immunological memory. Innate and adaptive immune systems are further cross-regulated by cytokine 
release of phagocytes modulating the adaptive immunity by T cell stimulation and regulatory T cell (Treg) 
inhibition, and upregulation of the innate immune system by release of immunological mediators by Th1 
cells. 
 
As the adaptive immune response needs several days to develop, the innate immunity is 
the essential system during the first hours of infection. It is rapidly activated after 
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signaling molecules typical for attacking pathogens have been recognized (Kumar et al., 
2009). However, adaptive and innate immune systems are intimately interwoven 
(Figure  IA-1). Several regulatory pathways activated by the innate immune system also 
control many aspects of the adaptive immune response (Medzhitov, 2001). The 
combination of innate and adaptive immunity is thus central to the efficacy of the 
mammalian immune system. The innate immune system rapidly recognizes and 
eliminates invading microorganisms resulting in minimal self-damage, whereas the 
adaptive immune system mediates the protection against the re-infection with the same 
pathogen by generation of memory B and T cells (Palm and Medzhitov, 2009). 
 
IA.2 Pattern recognition receptors 
Pattern recognition receptors (PRRs) are found in a wide array of eukaryotes including 
amoebae (Walk et al., 2011), insects (Anderson, 2000; Hashimoto et al., 1988), plants 
(Segonzac and Zipfel, 2011) and vertebrates (Janeway, Jr., 1992). The germ-line 
encoded receptors of the innate immune system recognize pathogens by characteristic 
molecules, generally referred to as “pathogen-associated molecular patterns” (PAMPs) 
(Janeway, Jr., 1989). PAMPs are signature molecules that are largely invariant, unique 
to large groups of evolutionarily related microorganisms, central to their metabolism or 
structure and hence essential for their survival. This principle allows microbial and host 
molecules to be distinguished permitting a limited number of receptors to recognize 
essentially all pathogens (Medzhitov, 2001).  
PRRs may be categorized as follows (Figure  IA-2): i) Membrane-bound PRRs. 
Examples include Dectin-1 for the detection of β-glucans in fungal cell walls 
(Goodridge et al., 2011), mannose receptor to bind mannose on the surface of microbes 
(Apostolopoulos and McKenzie, 2001), and the prominent class of Toll-like receptors 
(TLRs) that recognize a wide variety of microbial PAMPs and are located on cell or 
endosomal membranes (Mogensen, 2009). ii) Cytoplasmic receptors. Examples include 
the NOD-like receptors (NLRs) recognizing nucleotides and cell wall components 
(Fukata et al., 2009), RIG-like receptors (RLRs) for viral RNA (Ramos and Gale, Jr., 
2011), and the “interferon stimulatory DNA” (ISD) sensors for viral DNA (Ishii et al., 
2008). iii) Secreted PRRs recognize PAMPs, such as mannan-binding lectin (MBL) 
(Dommett et al., 2006). As part of the complement system of the innate immune 
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response, MBL is involved in the opsonization of the cell surface of microbes 
enhancing phagocytosis (Takahashi, 2011). 
 
Figure  IA-2 The localization of pattern recognition receptors 
TLRs are membrane-spanning receptors on cellular or endosomal membranes. They bind PAMPs using 
leucine rich repeat (LRR) domains and initiate intracellular signaling through their C-terminal 
Toll/interleukin-1 receptor (TIR) domains. RLRs possess a helicase domain to bind viral RNA activating 
CARD-dependent signaling. NLRs have a central nucleotide-binding oligomerization domain (NOD), and 
a C-terminal LRR domain, which analogously to TLRs, recognizes the microbial molecules. DAI and 
AIM2 belong to the group of DNA sensor proteins, MBL opsonizes the cell surface of microbes 
enhancing phagocytosis. (Adapted from: Mogensen, 2009) 
 
 
IA.3 TLRs: Key players in the innate immune response 
The most extensively studied class of PRRs is the family of Toll-like receptors (TLRs). 
TLRs derive their name from the homologous receptor Toll in Drosophila melanogaster  
(Medzhitov et al., 1997) discovered in 1988 as a protein central to establishing the 
embryonic dorsal-ventral pattern (Hashimoto et al., 1988). Toll was later linked to the 
activation of the immune response following fungal infection (Lemaitre et al., 1996). 
Structurally, TLRs are single-pass, type-1 transmembrane glycoproteins. The single, 
membrane-embedded α-helix connects an extracellular, ligand-binding domain 
primarily constituted by leucine-rich repeats (LRRs) with an intracellular 
Toll/interleukin-1 receptor (TIR) domain (Akira and Takeda, 2004; Slack et al., 2000). 
Extracellular recognition of suitable patterns leads to receptor dimerization which 
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initiates intracellular signaling culminating in the translocation of the transcription 
factors nuclear factor κB (NF-κB) and interferon regulatory factor 3 and 7 (IRF3 and 
IRF7) into the nucleus activating genes of the immune response (Gay and Gangloff, 
2007). 
 
IA.3.1 The family of TLRs and their ligands 
The human genome encodes eleven TLRs. However, the human gene for TLR11 is 
interrupted by a stop codon preventing its functional expression. Mice encode TLRs 1 
to 13 but cannot express TLR10 (Leulier and Lemaitre, 2008; Roach et al., 2005). Each 
TLR is specific for distinct ligands. Extracellular TLRs (TLR1, 2, 4, 5, 6 and 10) 
specialize in recognizing surface-associated ligands of microbes (cell wall components; 
viral, fungal and parasitic products), whereas endosomal TLRs (TLR3, 7, 8 and 9) bind 
pathogen-derived DNA and RNA fragments.  
 
Table  IA-1 Human TLRs and microbial ligands from various species 
 Ligands Origin 
TLR1 Triacyl lipopeptides 
Soluble factors 
Outer surface protein A (OspA) 
Bacteria, Mycobacteria 
Neisseria meningitides 
Borrelia burgdorferi 
TLR2 Lipoproteins/lipopeptides 
Peptidoglycan 
Lipoteichoic acid 
Lipoarabinomannan 
Phospholipomannan 
Zymosan 
Hemagglutinin 
Various pathogens 
Gram-positive bacteria 
Gram-positive bacteria 
Mycobacteria 
Candida albicans 
Saccharomyces cerevisiae 
Measles virus 
TLR3 dsRNA Viruses 
TLR4 Lipopolysaccharide 
Mannan 
Glycoinositolphospholipids 
Taxol 
Envelope proteins 
Gram-negative bacteria 
Candida albicans 
Trypanosoma cruzi 
Plants 
Mouse mammary tumor virus 
TLR5 Flagellin Bacteria 
TLR6 Diacyl lipopeptides 
Peptidoglycan 
Zymosan 
Mycoplasma 
Gram-positive bacteria 
Saccharomyces cerevisiae 
TLR7 ssRNA Viruses 
TLR8 ssRNA Viruses 
TLR9 Unmethylated CpG-rich DNA Bacteria and viruses 
TLR10 Unknown Unknown 
Compiled from Akira et al., 2006; Chang, 2010; Gay and Gangloff, 2007; and Kumar et al., 2009. 
 
Table  IA-1 illustrates the diversity of ligands from microbial pathogens that induce 
TLR-based immune responses. Recognition includes lipopeptides by TLR2 in complex 
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with TLR1 or TLR6 (Takeda et al., 2002; Takeuchi et al., 2001), double-stranded RNA 
by TLR3 (Alexopoulou et al., 2001), lipopolysaccharides by TLR4 (Poltorak et al., 
1998), flagellin by TLR5 (Hayashi et al., 2001), single-stranded RNA by TLR7 and 
TLR8 (Heil et al., 2004; Hemmi et al., 2002), unmethylated CpG motifs in DNA by 
TLR9 (Hochrein et al., 2004), and many others. One receptor can recognize several 
structurally unrelated ligands, and germ-line mutations have demonstrated the 
participation of additional adaptor proteins such as CD14, CD36, MD-2 and Dectin-1 
for full signaling efficacy by TLR2 and TLR4 complexes (Beutler, 2009; Piccinini and 
Midwood, 2010). 
 
IA.3.2 Damage-associated molecular patterns (DAMPs) 
Alongside microbial derived components, TLRs also recognize damage-associated 
molecular patterns (DAMPs), host endogenous molecules released and distributed 
following stress, tissue damage and cellular diseases. DAMPs induce strong 
inflammatory immune responses and lead to the recruitment of phagocytes. A list of 
known endogenous ligands are summarized in Table  IA-2. 
 
Table  IA-2 Endogenous TLR ligands 
 Ligands 
TLR2 Glycoprotein 96 (gp96, or heat shock protein 96, HSP96) 
Serum amyloid A 
HSP60 
HSP70 
High-mobility group protein B1 (HMGB1) 
Biglycan 
Alzheimer’s amyloid β peptide 
TLR3 self dsRNA 
TLR4 Extra domain A (EDA) of fibronectin 
Oligosaccharides of hyaluronic acid 
Fibrinogen 
Tenascin-C 
HSP22 
HSP60 
HSP70 
High-mobility group protein B1 (HMGB1) 
Biglycan 
TLR7 self ssRNA 
TLR8 self ssRNA 
TLR9 self DNA 
Chromatin-IgG complexes 
Compiled from Chang, 2010; Gay and Gangloff, 2007; Huang and Pope, 2010, and Liu et al., 2011. 
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Loss of immune response dampening and innate immunity down-regulation results in 
persistent expression of pro-inflammatory cytokines leading to inflammation and 
autoimmune diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE), atherosclerosis and ischemia-reperfusion (I/R) injury (Farrar et al., 2011; Huang 
and Pope, 2010; Kovach and Standiford, 2011).  
 
TLRs are found in a wide range of cell types including cells of the innate immune 
system (macrophages, dendritic cells, neutrophils and natural killer cells), adaptive 
immune system (T cells, B cells), tissues (endothelial cells, epithelial cells, skin 
keratinocytes, fibroblasts), cancer cells, and many others. This variety demonstrates the 
importance of TLRs in the regulation of innate and adaptive immune responses after 
pathogen invasions but also in tissue repair and regeneration (Chang, 2010). 
 
IA.3.3 TLR signaling pathways 
Signal initiation by TLR is elicited by the ligand-induced dimerization of two TLR 
molecules. Extracellular or endosomal ligands induce dimerization of the corresponding 
TLR domains leading to the dimerization of the cytosolic Toll/interleukin-1 receptor 
(TIR) domains and conformational changes required to recruit other TIR domain-
containing adaptor molecules (O'Neill and Bowie, 2007). Signaling by all TLRs except 
TLR3 involves one such adaptor molecule “myeloid differentiation primary-response 
gene 88” (MyD88), whereas TLR3 instead signals through “TIR domain-containing 
adaptor protein inducing interferon-β” (TRIF). “MyD88-adaptor-like” protein (MAL) is 
involved in signaling alongside MyD88 in TLR2 and TLR4, whereas TLR4 and TRIF 
are linked by “TRIF-related adaptor molecule” (TRAM) (O'Neill, 2008). The adaptors 
trigger a number of signaling cascades through phosphorylation, ubiquitination and 
protein-protein interactions (Mogensen, 2009) culminating in the translocation of 
transcription factors into the nucleus where they regulate the expression of interferons 
and proinflammatory cytokines (Figure  IA-3). 
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Figure  IA-3 TLR signaling 
Dimerization of TLRs induces the recruitment of TIR domain-containing adaptor molecules MyD88 
(TLR5, TLR7, TLR8, TLR9), Mal and MyD88 (TLR2 and TLR4), TRIF (TLR3), or TRAM and TRIF 
(TLR4). The MyD88-dependent pathway leads to the recruitment of IRAK4, IRAK1 and IRAK2 and the 
ubiquitination of TRAF6, which activates TAK1. TAK1 in turn activates the IKK complex (NEMO, 
IKKα, IKKβ), leading to phosphorylation and degradation of the inhibitory IκB. The activated   
transcription factor NF-κB is translocated into the nucleus and induces the production of pro-
inflammatory cytokines. TAK1 also triggers the activation of MKK proteins and the activation of 
transcription factor AP-1. The TRIF-dependent pathway involves the recruitment of TRAF3 and TANK, 
following the activation of the IKK-related kinases TBK1 and IKKε. The kinases directly phosphorylate 
the transcription factors IRF3 and IRF7, which are translocated into the nucleus to activate the expression 
of type-I interferons. The TRIF-dependent pathway is further linked to NF-κB activation through 
recruitment and activation of TRAF6. (Adapted from: Mogensen, 2009) 
 
The MyD88-dependent pathway culminates in the activation of NF-κB and the 
production of pro-inflammatory cytokines. The pathway involves i) “IL-1-receptor-
associated kinases” (IRAKs), ii) the ubiquitin-protein ligase “tumour-necrosis-factor-
receptor-associated factor 6” (TRAF6), that generates Lys63-linked polyubiquitin 
chains on itself, iii) the “transforming growth factor-activated protein kinase 1” (TAK1) 
and iv) “NF-κB-essential modulator” (NEMO) (Mogensen, 2009). NEMO forms part of 
v) the “ ‘inhibitor of nuclear factor-κB’ (IκB)-kinase” (IKK) complex together with the 
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proteins IKK-α and IKK-β. IKK is activated and site-specifically phosphorylates vi) IκB 
releasing vii) NF-κB which translocates to the nucleus (Akira and Takeda, 2004; 
Hayden and Ghosh, 2008). In a second MyD88-dependent pathway, the activation of 
members of the “ ‘mitogen-activated protein kinase’ (MAPK) kinase” (MKK) family 
leads to the phosphorylation and activation of p38 and ultimately to the activation of the 
“transcription factor activator protein 1” (AP1) (Chang and Karin, 2001). 
 
The MyD88-independent, TRIF-dependent pathway triggers the expression of type I 
interferons (IFN) and IFN-inducible genes by phosphorylation and activation of the 
transcription factors “interferon regulatory factor 3” (IRF3) and IRF7 through IKK-
related kinases “ ‘TRAF associated NFκB activator’ (TANK)-binding kinase 1” (TBK1) 
and IKKε (Fitzgerald et al., 2003; Sharma et al., 2003). This pathway also cross-links 
with the NF-κB signaling by recruitment of TRAF6, which leads to ubiquitination and 
activation of TAK1 and subsequent  activation of the IKK complex (Sato et al., 2003). 
In addition to pathways activating the cellular immune response, it appears that at least 
TLR2, TLR3 and TLR4 can induce apoptosis by activating death signaling pathways 
(Aliprantis et al., 1999; Gay and Gangloff, 2007; Kaiser and Offermann, 2005). 
The complexity of TLR-induced signaling requires precise regulation as the excessive 
or erroneous activation of pathways can lead to severe disease. TLR4 signaling is 
correspondingly controlled by the two competing adaptor protein pairs MAL/MyD88 
and TRAM/TRIF, involved in two independent but sequentially activated pathways 
regulated by the endocytosis of the TLR4 complex (Kagan et al., 2008). Apparently 
TLR4 in the plasma membrane induces MAL/MyD88 signaling while TLR4 
endocytosis activates TRAM/TRIF signaling (Kagan et al., 2008). 
 
Negative regulation of TLR-dependent signaling was observed by the TIR adaptor 
“sterile alpha- and armadillo motif-containing protein” (SARM) that competes with 
TRIF-dependent signaling in human cells (Carty et al., 2006). “Suppressor of cytokine 
signaling 1” (SOCS1) mediates the degradation of the TIR adaptor MAL and is thus a 
negative regulator of TLR2 and TLR4 pathways (Mansell et al., 2006). Further negative 
regulation by competition, degradation or deubiquitination include the IRF-3-
controlling “prolyl isomerase 1” (Pin1), the protein A20 which removes Lys63-linked 
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polyubiquitin chains from TRAF6, and the formation of heterodimers of MyD88 with 
the splice variant MyD88s, which can no longer phosphorylate IRAK-1 or interact with 
IRAK-4 (Wang et al., 2009). 
 
IA.4 The molecular basis of recognition by TLRs 
IA.4.1 The extracellular LRR domain 
TLRs are type-I membrane proteins, in which a single transmembrane α-helix connects 
the extracellular (endosomal) ligand-binding domain with the cytosolic TIR domain. 
The extracellular domain (ECD) of TLRs is composed of 16-28 consecutive LRR units 
forming a curved horseshoe-like shape (Matsushima et al., 2007).  
 
 
Figure  IA-4 The structure of the extracellular domain of TLRs 
(A) The LRR consensus sequence for TLRs. The residues xLx (yellow) form a β-strand that aligns with 
that of neighboring LRRs. (B) Extracellular domain of TLRs using the example of TLR3 (Liu et al., 
2008a), with N-linked glycosylation and LRR-NT and LRR-CT capping regions. For a detailed 
description of structural features, see the text below. 
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LRRs generally generate right-handed helical or solenoid structures in which each 
repeat adds one turn to the solenoid. Each LRR may be considered as consisting of a 
conserved and a variable region, where the conserved elements entail the motif 
LxxLxLxxNxL (L, hydrophobic aa; N, polar uncharged aa; x any aa), the residues xLx 
at positions 3 through 5 of which form a β-strand that aligns with that of neighboring 
repeats to generate a parallel β-sheet (Matsushima et al., 2007) (Figure  IA-4, A). The 
variable parts either form an α-helix, a 310-helix or an extended structure (depending on 
its length) plus loops on either side connecting it with the β-strands. Conserved, 
hydrophobic (mostly aliphatic) residues as well as conserved asparagines point to the 
interior forming a stable hydrophobic core, while non-conserved residues face the 
exterior (Kajava, 1998; Kobe and Kajava, 2001). Because β-strands of each LRR are 
narrower than the helices, LRR domains adopt a curved conformation, in which the β-
sheet forms the concave surface and the non-β portions form the convex surface (Botos 
et al., 2011; Kajava, 1998) (Figure  IA-4, B). 
The LRR domain of TLRs is protected N- and C-terminally by two small capping 
modules denoted LRR-NT and LRR-CT domains. In TLRs these contain disulfide 
bridges and shield the hydrophobic LRR core from the hydrophilic solvent (Jin and Lee, 
2008b)  (Figure  IA-4, B). 
 
IA.4.2 TLR crystal structures 
The first crystal structure of an TLR-ECD was that of human TLR3 (Bell et al., 2005; 
Choe et al., 2005). In total, five TLR/ligand complexes have been crystallized and their 
structures solved to date. Complexes include TLR1/TLR2/Pam3CSK4 (Jin et al., 2007), 
TLR4/MD-2/LPS (Kim et al., 2007; Park et al., 2009), TLR3/dsRNA (Liu et al., 2008a), 
TLR2/TLR6/Pam2CSK4 (Kang et al., 2009), and TLR5/flagellin (Yoon et al., 2012). All 
structures reveal the typical horseshoe-like shape. They can, however, not be 
superimposed due to variations in curvature (Figure  IA-5). 
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Figure  IA-5 TLR-ligand structures 
Side and top views of (A) TLR2/TLR1/Pam3CSK4 (Jin et al., 2007) and (B) TLR2/TLR6/Pam2CSK4 
(Kang et al., 2009). C-terminal domains of TLR1, TLR2 and TLR6 were replaced by hagfish VLR 
domains (highlighted in grey) to promote crystallization. (C) TLR3/dsRNA (Liu et al., 2008a),  (D) 
TLR4/MD-2/LPS (Park et al., 2009). The lipid A component of LPS is colored red and the inner core 
carbohydrates of LPS is colored pink. (E) TLR5/flagellin (Yoon et al., 2012). C-terminal domain of 
TLR5 was replaced by hagfish VLR domain (highlighted in grey) to promote crystallization. In all TLR 
complexes ligand binding induces TLR dimerization in the C-terminal regions.  
 
The LRR motifs constitute a rigid yet adaptable scaffold for the formation of 
TLR/ligand interactions. Whereas most LRR proteins bind ligands through their 
concave surfaces, ligand interaction in TLRs mainly occurs on the ascending lateral 
surface (Botos et al., 2011), but can involve the concave (TLR4, TLR5) as well as the 
convex (TLR2/TLR1, TLR2/TLR6, TLR4) surface (Figure  IA-5). Hydrophobic (TLR1, 
TLR2, TLR3 and TLR6) as well as polar interactions (TLR3-dsRNA, TLR5) are 
developed during ligand interaction (Jin et al., 2007; Liu et al., 2008a). 
 
IA.4.3 Ligand binding induces dimerization and signal transduction 
Ligand binding to the lateral surface of TLRs results in dimerization of the extracellular 
domains (Figure  IA-5). In the TLR2/TLR1 and TLR2/TLR6 complexes, direct protein-
protein interactions occur in the central LRRs involving residues immediately adjacent 
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to the ligand binding pockets. In the TLR3/dsRNA complex, by contrast, TLR3/TLR3 
interactions occur only at the LRR-CT (Botos et al., 2011). In the TLR4/MD-2/LPS 
complex, the adaptor protein together with the LPS mediates the receptor interaction 
(Park et al., 2009). In the TLR5/flagellin complex, the flagellin domain is located on the 
lateral side of TLR5, forming a 1:1 heterodimer. Two heterodimers further oligomerize 
to a symmetric 2:2 complex (Yoon et al., 2012). The fact that ligand interaction 
involves the lateral surface of the TLRs in all known TLR/ligand structures is 
corroborated by the observation that this surface is the only part of the molecule that is 
not N-glycosylated leaving it free for protein-protein and protein-ligand interaction 
(Botos et al., 2011). 
 
 
Figure  IA-6 Dimerization triggers signal transduction 
Structural model of full length TLR3/dsRNA complex. The model is based on the TLR3/dsRNA structure 
(Liu et al., 2008a) and a TLR3 TIR domain homology model based on the TLR10 TIR structure (Nyman 
et al., 2008). The membrane portions have been modeled as α-helices. (Source: Botos et al., 2011). 
 
Ligand-induced TLR dimerization invariantly results in the C-terminal regions being 
placed in close physical proximity (Figure  IA-5). This then allows for the alignment of 
the transmembrane α-helices and for the dimerization of the cytoplasmic TIR domains 
(Figure  IA-6). This in turn triggers the activation of the signaling cascades. 
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IA.5 Toll-like receptor 2: A promising drug target 
All TLRs are potential therapeutic targets in that i) they are overexpressed in certain 
diseases, ii) corresponding knockout mice are resistant to these diseases, iii) ligands 
exacerbate inflammation in disease models and iv) genetic differences in TLRs correlate 
with risk of disease (Hennessy et al., 2010). Furthermore, TLRs operate in an early 
stage of inflammation signaling and might therefore be preferred for modulation.  
TLR2 is by far the most intensively studied member of the family. It is expressed on a 
large variety of human cell types, and recognizes a wide array of ligands more than any 
other member of the TLR family and not restricted to diacylated and triacylated 
lipopeptides for which crystal structures have been solved (Figure  IA-5). Ligands 
include peptidoglycan (PGN) and lipoteichoic acid (LTA) from Gram-positive bacteria 
(Mitsuzawa et al., 2001), lipoarabinomannan from mycobacteria (Underhill et al., 
1999), Zymosan from fungi; lipopolysaccharides (LPS) from spirochetes (Werts et al., 
2001), hemagglutinin protein from measles virus (Bieback et al., 2002), and others 
(Chang, 2010; Gay and Gangloff, 2007). Known endogenous damage signals amongst 
others are HSP60 (Prakken et al., 1997), HSP70 (Asea et al., 2002), gp96 (Huang et al., 
2009), and HMGB1 (Huang and Pope, 2010) (see also Table  IA-1 and Table  IA-2). 
The complexity of ligand recognition and activation and inactivation of signaling 
pathways presumes a precise regulation, but the mechanisms are not yet fully 
understood. It is known that uncontrolled or disregulated activation of TLR2 can cause 
severe diseases in humans. TLR2 antagonists as well as agonists are currently in 
development to treat various human diseases and especially TLR structures in complex 
with their ligands can contribute to rationally design TLR drugs (Hennessy et al., 2010). 
 
IA.5.1 TLR2-related diseases 
The detection of microbial and endogenous products by TLR2 and other TLRs induces 
the release of large amounts of inflammatory cytokines and chemokines, such as 
TNF-α, IL-1β and IL-6. A corresponding hyperactivation of immune cells by bacteria 
through TLR2 stimulation can lead to septic shock pathology, clinically characterized 
by abnormal coagulation, profound hypotension, and organ failure (Cohen, 2002; 
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Hotchkiss and Karl, 2003; Meng et al., 2004). Ulcerative colitis, a form of inflammatory 
bowel diseases (IBDs), is associated with a Arg753Gly polymorphism of TLR2 (Pierik 
et al., 2006) and causes chronic intestinal inflammation induced by the commensal flora 
(Fukata et al., 2009) (Figure  IA-8, C). 
 
Figure  IA-7 DAMP-mediated vicious inflammation cycle 
DAMPs released from injured tissue activate TLRs and leads to the induction of intracellular signaling 
cascades, the activation of transcription factors and the production of pro-inflammatory cytokines. The 
mediators stimulate and recruit more immune cells that lead to further cell necrosis, which in turn releases 
more DAMPs.  
 
Likewise, the recognition of DAMPs released from inflamed tissues can lead to chronic 
inflammation, caused by a self-promoting cycle in which more inflammatory mediators 
are generated, leading to further activation of TLRs (Hennessy et al., 2010) (Figure 
 IA-7). TLR2- and TLR4-derived chronic inflammation can cause rheumatoid arthritis 
(RA) in synovial joints leading to destruction of cartilage and bone (Goh and Midwood, 
2011) (Figure  IA-8, B). Potentially an initial microbial infection or trauma induces 
tissue damage causing the release of endogenous TLR ligands and starting the cycle of 
inflammation (Santegoets et al., 2011). Examples of identified TLR2-dependent 
endogenous ligands involved in RA are biglycan and gp96 (Huang and Pope, 2010; 
Piccinini and Midwood, 2010). 
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The autoimmune disease systemic lupus erythematosus (SLE) is characterized by the 
destruction of organ tissue of the human body including skin, kidneys, joints and the 
central nervous system through autoantibodies (Figure  IA-8, A). In SLE patients with 
impaired apoptotic cell clearance, the release of HMGB1 induces autoantibody 
production in a TLR2-dependent manner (Urbonaviciute et al., 2008).  
TLR2 is also involved in the development of atherosclerosis, a chronic inflammatory 
disease of arteries that results in the formation of plaque and blood-vessel narrowing 
(Figure  IA-8, D). This can culminate in thrombosis and occlusion, resulting in a 
myocardial infarction or stroke (Huang and Pope, 2010). Transfection of carotid arteries 
of rabbits with cDNA encoding TLR2 or TLR4 induced atherosclerosis (Shinohara et 
al., 2007), and TLR2-/- mice exhibited decreased atherosclerotic plaques and decreased 
numbers of macrophages (Liu et al., 2008b). 
 
 
Figure  IA-8 Medical signs associated with TLR2-related diseases 
(A) The typical “butterfly rash” found in systemic lupus erythematosus. (B) Deformations of the hand 
caused by rheumatoid arthritis. (C) Ulcerative colitis of the transverse colon with granularity and 
friability of the mucosa. (D) Lesions in aorta of murine model of atherosclerosis. (Sources: (A) 
http://trialx.com/curebyte/2011/06/01/ (B) http://nihseniorhealth.gov/rheumatoidarthritis/toc.html (C) 
Fukata et al., 2009 (D) http://www.bcm.edu/mcb/?PMID=8876 
 
 
 
TLR2 is crucial in the development of ischemia/reperfusion (I/R) injury, a disease 
characterized by inflammatory tissue damage caused by reperfusion (restoration of 
blood flow) to a tissue after a period of ischemia (restriction in blood supply). It is 
associated with trauma, stroke, myocardial infarction, and solid organ transplantation 
(Arslan et al., 2010a). I/R injury after myocardial infarction increases infarct size 
(Arslan et al., 2010b) whereas it leads to acute kidney injury after renal transplantation 
(Farrar et al., 2011). HSP70-dependent TLR2 activation was observed in 
cardiomyocytes (Mathur et al., 2011) resulting in decreased cardiomyocyte contractility 
(Boyd et al., 2006). Ex vivo experiments with TLR2-knockout (TLR2-/-) hearts 
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increased heart performance in comparison to wild-type hearts after myocardial I/R 
injury (Sakata et al., 2007). Furthermore TLR2-/- mice are protected against endothelial 
dysfunction after myocardial I/R injury (Favre et al., 2007). Renal inflammation 
increases TLR2 and TLR4 expression in epithelium, thin limb and collecting ducts 
(Wolfs et al., 2002). However, renal I/R injury was reduced in TLR2-/- mice (Leemans 
et al., 2005). Likewise, the amount of brain damage and neurological deficits caused by 
a stroke were significantly less in mice deficient in TLR2 or -4 compared with WT 
control mice (Tang et al., 2007). TLR2 is also involved in lung diseases, such as asthma 
(Kovach and Standiford, 2011). More recently, TLR2 was identified as a primary 
receptor triggering neuroinflammation through Alzheimer-associated amyloid β peptide 
recognition (Liu et al., 2011).  
 
IA.5.2 TLR2 agonists  
Immunostimulatory TLR agonists can be used to induce a strong pro-inflammatory 
response in treating acute viral and bacterial infection (Hennessy et al., 2010). Several 
compounds, mainly small DNA or RNA fragments against TLR7, TLR8 and TLR9 are 
currently in clinical trials. Alternatively, TLR agonists are used to stimulate immune 
response in advanced stages of cancer to induce apoptosis of chemotherapy-resistant 
cancer cells. SMP-105, a drug with strong antitumor activities, consists of cell wall 
skeleton compounds of Mycobacterium bovis and was proven to enhance TLR2-
dependent immune response, such as the number of interferon-γ-producing cells and 
cytotoxic T lymphocytes, leading to reduced tumor growth (Murata, 2008). SMP-105 is 
currently in preclinical trials for the treatment of bladder cancer. 
 
IA.6 Antagonistic antibody inhibits TLR2 signaling 
The development of TLR2 antagonists to inhibit cytokine production during 
inflammation and autoimmunity diseases has become a major interest. One very 
promising candidate is the TLR2 specific monoclonal antibody OPN-305, a humanized 
version of the mouse IgG OPN-301 (also known as T2.5) based on a human IgG 
framework. The antibody was originally found to inhibit lipopeptide, PGN, LTA and 
heat inactivated Bacillus subtilis induced TNF-α production in HEK293 and murine 
RAW264.7 and primary macrophages, and thus to suppress septic shock in mice (Meng 
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G, 2004). The antibody cross-reacts with other TLR2s including human, pig and 
cynomolgus monkey TLR2, indicating that it is specific for a critical epitope yet 
conserved (Arslan et al., 2010b). 
Several results have shown that TLR2 inhibition with OPN-301 effectively reduces 
myocardial I/R injury and preserves cardiac function and geometry in vivo in mice. It 
thus has the potential as an effective treatment for patients with acute myocardial 
infarction (Arslan et al., 2010b). OPN-301 also provides significant protection from I/R 
injury in a murine model of kidney transplantation (Farrar et al., 2011). The antibody 
prevents pro-inflammatory cytokine release in RA tissue synovial explant cultures ex 
vivo (Ultaigh et al., 2011) and in a sepsis model in mice (Farrar et al., 2011). OPN-305 
was granted orphan status for the prevention of the I/R injury associated with organ 
transplantation and is currently tested in human trials. 
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IB Producing mouse/human Toll-like receptors 2 and 6 in 
insect cells using the baculovirus expression system 
In the past years increasingly more exogenous and endogenous TLR and especially 
TLR2 ligands have been identified (Table  IA-1, Table  IA-2). These ligands originate 
from taxonomically unrelated organisms and differ fundamentally in their structures. 
The first crystal structures of lipopeptides-bound TLR2/TLR1 and TLR2/TLR6 
complexes provide a first detailed structural insight into ligand recognition by TLR2 
complexes. However, this milestone is best regarded as a start rather than the end of 
understanding TLR2 and other TLRs with regard to their ability to distinguish and 
respond to such a diversity of molecules. The epitopes of other TLR2 ligands and their 
mode of recognition are still unknown, but there is evidence that further accessory 
molecules and co-receptors are necessary for PAMP and DAMP recognition, which 
directly bind to the TLR and/or the ligand.  
 
IB.1 TLR1/TLR2 and TLR2/TLR6 in complex with lipopeptides 
TLR1 and TLR6 share a high degree of sequence similarity and tandem arrangement in 
the human genome, indicative of a fairly recent gene duplication event (Roach et al., 
2005). Together with TLR2 they form a phylogenetically related subfamily (Chang, 
2010). TLR2 in complex with TLR1 or TLR6 is essential for the recognition of bacterial 
lipoproteins and lipopeptides (Figure  IB-1). These molecules are embedded with their 
lipid chains (acyl groups) in cell walls and membranes of a variety of microorganisms 
and trigger the immune response via TLR2/TLR1 and TLR2/TLR6 heterodimers 
(Takeda et al., 2002). Lipidated peptides/proteins are mostly triacylated bearing three 
lipid chains connected to the N-terminal cysteine of an amino acid chain. Mycoplasmal 
lipopeptides, by contrast, are only diacylated (Takeuchi et al., 2001). In triacylated 
lipopeptides a diglyceride or diacylated glycerol is bound to the N-terminal cysteine 
side-chain by a thioether bond while a third fatty acid is bound to the amino group of 
the same cysteine by an amide link. Diacylated lipopeptides like mycoplasmal 
“macrophage-activating lipopeptide-2 kDa” (MALP-2) lack the nitrogen bound fatty 
acid (Mühlradt et al., 1997).  
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Figure  IB-1 Chemical structures of lipopeptides 
Chemical structures of the diacylated lipopeptide MALP-2, the triacylated lipopeptides “outer surface 
protein A” (OspA) of B. burgdorferi and the synthetic lipopeptide Pam3CSK4. 
 
Triacylated lipopeptides are recognized by the complex of TLR2/TLR1, diacetylated 
lipopeptides by TLR2/TLR6 (Botos et al., 2011). TLR1 and TLR6 are therefore crucial 
in distinguishing tri- and diacylated lipopeptides and lipoproteins. Synthetic 
lipopeptides from which most amino acid residues have been removed still cause 
inflammation (Berg et al., 1994; Bessler et al., 1985; Seifert et al., 1990) implying that 
merely the acylated N-terminal cysteine is critical for recognition by TLRs. This was 
confirmed by the crystal structures of TLR2/TLR1/Pam3CSK4 (Jin et al., 2007) and 
TLR2/TLR6/Pam2CSK4 (Kang et al., 2009). In TLR6 the lipid channel that 
accommodates the third aliphatic chain of triacylated lipopeptides in TLR1 is blocked 
by two phenylalanines restricting TLR6 to diacylated lipopeptides (Figure  IB-2). 
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Figure  IB-2 Distinction of di- and triacylated lipopeptides by TLR1 and TLR6 
Pam2CSK4 binding pocket in the TLR2/TLR6 complex (left) and Pam3CSK4 binding pocket in the 
TLR2/TLR1 complex (right). The TLR6 channel is blocked by the two phenylalanines F343 and F365 
and therefore inaccessible for a lipid chain. (Source: Kang et al., 2009) 
 
IB.2 TLR2 accessory molecules and co-receptors 
Lipopeptide recognition by TLR2/TLR1 and TLR2/TLR6 complexes is enhanced by 
accessory molecules. CD14 was identified as a sensor molecule of triacylated 
lipopeptides (Nakata et al., 2006) whereas CD36 adopts this function for diacylated 
lipopeptides (Hoebe et al., 2005) facilitating ligand recognition by TLR2/TLR1 and 
TLR2/TLR6, respectively.  
TLR2 appears to require the help of PRR dectin-1 to recognize the fungal component 
zymosan (Gantner et al., 2003) whereas “macrophage receptor with collagenous 
structure” (MARCO) and CD14 are essential to bind the cell wall glycolipid TDM from 
Mycobacterium tuberculosis (Bowdish et al., 2009). Similarly, CD14 and MD-2 are 
essential for DAMP recognition by TLR2 (Piccinini and Midwood, 2010). 
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IC Aims of this work 
 
IC.1 Inhibition of mTLR2 with a monoclonal antibody 
The monoclonal antibody OPN-305 has previously been shown to efficiently inhibit the 
immune receptor TLR2, downstream cytokine release and hence the TLR2-mediated 
immune response. OPN-305 has successfully been used to treat chronic inflammatory 
diseases such as RA and I/R injury in vitro and in vivo, and the antibody is on its way to 
market authorization as a therapeutic drug. However, the mechanism of TLR2 inhibition 
by OPN-305 and its epitope is still unknown. The aim of this project was therefore to 
use structural methods such as crystallography and electron microscopy to provide 
structural information on the TLR2/OPN-305 complex so as to explain TLR2 silencing 
by OPN-305. For that purpose protocols for the purification of TLR2 and antibody as 
well as for the purification of the TLR2/Fab complex had to be established to obtain 
protein in amounts and degrees of purity suitable for crystallization and EM trials. Prior 
to antibody purification, antibody Fab fragments had to be generated by proteolytic 
cleavage. The crystallization conditions had to be modulated to improve crystal growth 
and quality. Furthermore, as TLR2 is a glycoprotein, the impact of glycosylation on 
crystallization had to be analyzed. In case of a successful structure determination of the 
TLR2/Fab structure, functional studies were to be performed to unravel the mechanism 
of TLR2 inhibition by OPN-305. Furthermore the novel structural information was to be 
compared to other TLR2 complex structures and published literature on TLR2 to fully 
analyze the structure. 
 
IC.2 Producing mouse/human Toll-like Receptors 2 and 6 in insect 
cells using the Baculoviral Expression System  
The only established expression clone of a TLR available in the department at the 
beginning of the work was a mTLR2 ECD construct with a C-terminal His6-tag 
previously used for antibody interaction experiments described in part IA. The first aim 
of this project was to design and generate new recombinant constructs to produce 
murine and human TLR2 and TLR6 ECDs. An optimized purification strategy with 
cleavable C-terminally fused, highly specific Fc-tag was to be established to improve 
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the speed, yield and reproducibility of purification. Furthermore, the signal peptide was 
to be replaced to increase the secretion rate of the protein. As previous attempts to 
produce TLR2 and TLR6 in bacterial expression systems had not been successful, 
protein production was to be planned for eukaryotic expression systems such as insect 
cells using the baculovirus expression system. For this purpose, gene constructs had to 
be cloned into the vector pFastbac following the production of the baculovirus-DNA 
and transfection into Sf21 insect cells to produce virus containing the TLR gene 
constructs. A virus production protocol had to be established, and the amplified virus 
was to be used to infect insect cell cultures to start the production of the recombinant 
target protein. After successful protein production, expression tests had to be performed 
to analyze the quality and quantity of protein production.  
Initially it was planned to use produced and purified TLR2 and TLR6 for crystallization 
in complex with MALP-2 to get a closer insight into the mechanism of lipopeptide 
recognition by TLRs. However, this aim was superseded when the crystal structure of 
the complex of TLR2, TLR6 and the synthetic lipopeptide Pam2CSK4 was published. 
However, as TLR2 plays a pivotal role not only in the recognition of bacterial 
lipopeptides but also of many other ligands such as peptidoglycan and zymosan (see 
Table  IA-1), and as other studies reveal that TLR2 needs other distinct co-receptors and 
accessory molecules for full efficacy to deal with the breadth of the ligand repertoire, 
recombinant production of TLR2 and TLR6 and other TLRs still remain an important 
prerequisite for the investigation of TLR interactions and structural analysis. Moreover, 
TLR2 and TLR6 can be used in studies to analyze the influence of antibody OPN-305 
on complex formation and/or ligand binding. 
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II Material and Methods 
IIA Standard materials 
IIA.1 Chemicals, enzymes, kits and standards 
If not stated otherwise, all chemicals used in this work were purchased in “pro analysis” 
grade from the following companies: Difco, Fermentas, Fluka, GE-Healthcare, 
Hampton Research, Invitrogen, Macherey-Nagel, Merck, Millipore, Promega, Qiagen, 
Roche, Roth, Sigma-Aldrich and Stratagene. 
 
Table  IIA-1 Enzymes 
Enzyme Source 
DNAse I Roche 
Lysozyme Fluka 
Papain Roche 
Platinum Pfx DNA Polymerase Invitrogen 
PNGase F New England Biolabs 
PreScission protease UWC 
Lysozyme Fluka 
Restriction endonucleases: 
BamHI, BglII, HindIII, NdeI, NheI, 
XhoI 
Fermentas 
 
T4 DNA Ligase Roche 
TEV protease HZI 
 
Table  IIA-2 Kits 
Name Company 
GeneJET Gel Extraction Kit Fermentas 
GeneJET DNA Purification Kit Fermentas 
GeneJET Plasmid Miniprep Kit Fermentas 
GeneJET Plasmid Maxiprep Kit Fermentas 
 
Table  IIA-3 Molecular weight standards 
Name Usage Company 
PageRuler Unstained Ladder SDS-PAGE Fermentas 
Precision Plus Protein All Blue 
Standard 
SDS-PAGE/Western Blot BioRad 
Smart Ladder Agarose gel electrophoresis Eurogentec 
Unstained Protein Molecular 
Weight Marker 
SDS-PAGE Fermentas 
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IIA.2 Crystallization screens 
To screen for crystallization conditions, the following commercial screens were used:  
Table  IIA-4 Crystallization screens 
Name Company 
AmSO4 Suite  
ComPAS Suite  
Cryos Suite  
JCSG Core I Suite  
JCSG Core II Suite  
JCSG Core II Suite  Qiagen 
JCSG Core IV Suite  
JCSG Core+ Suite  
MPD Suite  
PACT Suite  
PEGs Suite  
PEGs II Suite  
Protein Complex Suite  
Additive Screen Hampton Research Corp. 
Pre-Crystallization Test  
 
IIA.3 Further reagents 
Table  IIA-5 Further reagents 
Name Company 
BugBuster Protein Extraction Reagent Novagen 
CytoBuster Protein Extraction Reagent Novagen 
“Complete” protease inhibitor tablets Roche 
Ni-NTA Agarose Qiagen 
 
 
IIB Inhibition of Toll-like receptor 2 with a monoclonal 
antibody 
IIB.1 Expression and purification of mTLR225-587-His6 
The extracellular domain of mTLR2 (aa 1-587) was recombinantly expressed with a C-
terminal linked His6-tag in Sf21 insect cells in a 6 L scale, and in CHO lec3.2.8.1 cells  
(Stanley, 1989; Wilke et al., 2010) in a 35 L scale (Dr. Joop van den Heuvel, HZI, 
Braunschweig, Germany). The native N-terminal signal peptide (aa 1-24) which led to 
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the secretion of the protein into the medium was cleaved by the cell own signal 
peptidase during translocation of the protein through the cell membrane. After 72 h the 
cells were removed by centrifugation and the supernatant was then filtered, concentrated 
(Sf21 cells: 10x, CHO cells: 20x) and dialyzed against 50 mM Tris pH 8, 500 mM 
NaCl, and 5% glycerol. 0.1% sodium azide was added to prevent bacterial and fungal 
growth. The shipment to South Africa was done at 4 °C and took 3-4 days. 
Prior to purification a “Complete” protease inhibitor cocktail tablet, EDTA-free (Roche, 
Basel, Switzerland) was added to the protein solution and the sample centrifuged for 1 h 
at 16’500 rpm (Centrifuge RC6, Sorvall/Thermo Fisher Scientific, Massachusetts, 
USA). Initial purification was achieved by Ni-NTA chromatography (Qiagen, Hilden, 
Germany). The protein was immobilized and the column was washed with ~400 mL 
wash-buffer 1 (50 mM Tris pH 8, 300 mM NaCl, 10 mM imidazole) and ~75 mL wash-
buffer 2 (50 mM Tris pH 8, 300 mM NaCl, 40 mM imidazole). mTLR225-587 was eluted 
by stepwise addition of elution buffer (50 mM Tris pH 8, 50 mM NaCl; imidazole steps: 
100, 250, 500 mM). After elution, mTLR225-587 was diluted with 25 mM Tris pH 8, 
25 mM NaCl to reach an imidazole concentration below 50 mM. The protein was then 
further purified by anion exchange chromatography (MonoQ HR10/10, GE Healthcare, 
UK). The protein was eluted using a salt gradient running from 80 to 200 mM NaCl 
during 25 column volumes. The pure protein (purity > 95 %) was concentrated to 
2 mg/mL.  
 
IIB.2 Deglycosylation 
For deglycosylation, 10 units of PNGase F (New England Biolabs, Massachusetts, 
USA) were utilized per 10 µg of mTLR225-587 and incubated for 15 h at room 
temperature in 50 mM Tris pH 8, 50 mM NaCl. The protein was either immediately 
used for complex formation or shock frozen in liquid nitrogen and stored at -80 °C. 
 
IIB.3 Papain digestion and purification of OPN-305 
The antibody OPN-305 was provided by Opsona Therapeutics (Dublin, Ireland) in 
10 mg/mL stocks in 25 mM sodium citrate pH 4.5 and 125 mM NaCl. The antibody was 
shock frozen in liquid N2 and stored at -80 °C until usage. For papain cleavage of the 
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antibody, the enzyme was first activated by incubation in 100 mM Tris pH 8, 20 mM L-
cysteine for 30 min at 37 °C, and the antibody buffer was exchanged by adding 100 mM 
Tris pH 8. Cleavage was initiated by mixing activated papain and antibody (mass ratio 
1:20) and incubation for at least 8 h at 37 °C. Size exclusion chromatography (Superdex 
200 16/60, GE Healthcare) with running buffer containing 50 mM Tris pH 8, 50 mM 
NaCl was performed to separate the fully cleaved antibody from incompletely cleaved 
molecules. Incompletely cleaved antibody was pooled and used as part of the next 
digestion. OPN-305 Fab fractions were concentrated and further purified performing a 
second run of size exclusion chromatography. OPN-305 Fab was stored at -80 °C after 
shock freezing in liquid N2. 
 
IIB.4 Purification of the mTLR225-587/Fab complex 
mTLR225-587 and OPN-305 Fab were mixed in a molar ratio of 1:2 and subjected to size 
exclusion chromatography (Superdex 200 16/60, GE Healthcare) using 25 mM Tris pH 
8, 25 mM NaCl as running buffer. The complex fractions were diluted to 12 mM Tris 
pH 8, 12 mM NaCl with water and concentrated to 20 mg/mL prior to crystallization 
setups. 
 
IIB.5 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein samples were analyzed by SDS-PAGE. This method separates proteins by an 
electric field dependent on their molecular weight. For this purpose proteins are 
denatured by incubation with a reducing agent and boiling. Proteins are further masked 
with the strongly negative charged substance sodium dodecyl sulphate (SDS) giving all 
proteins an almost equal charge to size ratio. This allows the separation by size through 
a porous, polymer matrix. During this discontinuous system (Laemmli, 1970) protein 
samples are first concentrated in a stacking gel before they are separated in a separating 
gel. The two gels differ in pH, ionic strength and pore dimension.  
10 µL of protein sample were mixed with 3 µL of SDS-containing 8x sample buffer 
following incubation of the sample for 5 min at 96 °C to ensure complete denaturing. 
To prevent breaking of disulfide bridges that link heavy and light chain of antibodies, 
8x sample buffer without the reducing agent β-mercaptoethanol was used in case of 
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samples containing OPN-305 antibody. The samples were applied to the stacking gel 
and the gel was run at constant 40 mM for 33 min. After the run the gel was stained for 
15 min in staining solution and excess stain removed by incubation of the gel in 
destaining solution. Gels were air dried in framings between cellophane foil (BioRad, 
California, USA). 
 
12 % separating gel: 12 mL acrylamide/bisacrylamide 30 % (w/v)/0.8 % (w/v) 
    7.6 mL 1.5 M Tris/HCl, pH 8.8 
    300 µL 10 % (w/v) SDS 
10 mL H2O 
    40 µL TEMED 
    100 µL 25 % (w/v) APS 
 
5 % stacking gel:  1.5 mL acrylamide/bisacrylamide 30 % (w/v)/0.8 % (w/v) 
    2.5 mL 0.5 M Tris/HCl, pH 6.8 
    5.9 mL ddH2O 
    15 µL TEMED 
    25 µL 25 % (w/v) APS 
 
8x sample buffer:  16 mL 10 % SDS 
    4 mL glycerol 
    2.2 mL Tris/HCl, pH 6.8 
    800 µL β-mercaptoethanol 
    1 spatula tip bromophenol blue 
 
Staining solution:   0.25 % (w/v) Coomassie Brilliant Blue R-250 
30 % (v/v) ethanol 
10 % (v/v) acetic acid 
 
Destaining solution:  40 % (v/v) ethanol 
10 % (v/v) acetic acid 
 
IIB.6 Native PAGE 
The native PAGE was performed according to standard SDS-PAGE, but no SDS and 
reducing agent were used in the electrophoresis solutions and the gel to prevent 
denaturing of the proteins. The run was done on ice using a low voltage of 100 V to 
avoid overheating of the gel and thus denaturing of the proteins.  
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IIB.7 Concentration of protein solutions 
Protein samples of OPN-305, TLR2 and TLR2/Fab complex were concentrated by 
ultracentrifugation using Vivaspin-2, -6- and -20 concentrators (Sartorius, Göttingen, 
Germany) with a MW cut-off of 10 kDa. The absorption at 280 nm was measured 
during the process. Centrifugation was terminated once the desired protein 
concentration was reached (see  IIB.8). If reduction of buffer or salt concentration of a 
sample was required, the concentrated protein solution was diluted with suitable buffer 
and re-concentrated to desired volume. 
 
IIB.8 Protein concentration quantification 
Amino acids residues with aromatic side chains absorb UV light at a wavelength of 
280 nm. The protein concentration in a sample were determined by measurement of the 
absorption at 280 nm (A280) against the sample buffer using a Nanodrop ND-1000 
spectrophotometer (peqLab, Erlangen, Germany). For concentration quantification after 
ultracentrifugation (see  IIB.7), the flow through of the Vivaspin concentrators was used 
as reference solution. The molar extinction coefficient ε280 for each protein was 
calculated in silico with the software VectorNTI (Invitrogen) from its amino acid 
composition. 
According to the Beer-Lambert law 
    
d
A
c
⋅
=
ε
280
    Equation IIB-1
 
the concentration c can be calculated if the values for A, d, and ε are known. d is the 
thickness of the measuring chamber and defined by the Nanodrop design. Protein 
concentration of single proteins was only determined if the target protein was the main 
protein fraction in a solution with negligible contaminations, as this method cannot 
distinguish between different proteins in a mixture.  
 
IIB.9 Mass spectrometry 
For electrospray ionization mass spectrometry (ESI-MS) of OPN-305 Fab, the sample 
buffer was desalted and exchanged to 10 mM ammonium acetate pH 5 using a PD-10 
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column (GE Healthcare). The sample was concentrated to 10.8 mg/mL (220 µM). Mass 
spectrometry was performed by Central Analytical Facilities (University of 
Stellenbosch, Bellville, South Africa). 
 
IIB.10 Modeling of OPN-305 
The OPN-305 Fab heavy chain and light chain variable domains were modeled by 3D 
structure prediction using SWISS-Model (Arnold et al., 2006; Kiefer et al., 2009; 
Peitsch et al., 1995). Modeling is based on the comparison of the target sequence with 
structures in the Protein Data Bank (PDB). The pipeline automatically selects suitable 
templates based on a Blast (Altschul et al., 1997), the experimental quality of the 
templates, bound substrate molecules, or different conformational states of the template. 
Model quality is estimated by calculating global (the whole model) and local (individual 
residues) scores. The global scoring function QMEAN4 is a linear combination of four 
structural descriptors using statistical potentials: A torsion angle potential over three 
consecutive amino acids, two distance-dependent interaction potentials, and a solvation 
potential to investigate the burial status of the residues (Benkert et al., 2008). The 
quality estimate ranges between 0 and 1 with higher values for better models. In 
addition, a Z-score of the QMEAN4 provides a relation to scores obtained for high-
resolution X-ray crystallography structures and represents a likelihood that the model is 
of comparable quality to experimental structures (Benkert et al., 2011). Models of low 
quality are expected to have strongly negative QMEAN Z-scores. The local score 
QMEAN is an estimate of the expected structural inaccuracy for each position in the 
model with small values corresponding to regions in the model being potentially more 
reliable. The local score ANOLEA calculates the atomic empirical mean force potential 
and is used to assess packing quality of the models (Melo and Feytmans, 1998). Energy 
calculations on the amino acid chain are performed to evaluate the "Non-Local 
Environment" of the atoms in the molecule and are displayed in a plot representing the 
energy for each amino acid of the protein chain. Negative energy values (in green) 
represent favorable energy environment whereas positive values (in red) unfavorable 
energy environment for a given amino acid (see results  IIIA.3.1). 
The modeled structure of the OPN-305 Fab variable domain was aligned with the 
crystal structure of b12 (PDB code 2NY7; (Zhou et al., 2007)), an antibody Fab 
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fragment with identical constant domain sequence to OPN-305, in UCSF Chimera 
(Goddard et al., 2007; Pettersen et al., 2004).  Using b12 as a framework, the variable 
domain of b12 was replaced by the modeled OPN-305 variable domain. 
 
IIB.11 Electron microscopy 
IIB.11.1 Specimen preparation and EM of mTLR225-587/Fab 
A sample of mTLR225-587/Fab in 25 mM Tris pH 8, 25 mM NaCl was diluted to 39 nM 
and 3 µL were applied on a charged carbon coated grid. After 30 s the grid was held 
briefly and successively into two drops of H2O and two drops of 2 % uranyl acetate 
(wt/vol) staining solution. Excess solution was carefully soaked up with filter paper. 
The images were collected on a LEO 912 Omega transmission electron microscope 
(Zeiss, Oberkochen, Germany) operated at an acceleration voltage of 125 kV at a 
magnification of x48000 and a defocus value between 0.5 and 1.0 µm. Low dose images 
were collected with a 2k x 2k Proscan CCD camera using the TCL software (Tietz 
Video and Image Processing Systems, Gauting, Germany)  
 
IIB.11.2 Referenced-based single-particle reconstruction 
Images were converted to mrc format and individual particles selected using the 
program sparx (Hohn et al., 2007). Mathematical image analysis were carried out with 
the software SPIDER (Frank et al., 1981; Frank et al., 1996). The particles were binned 
by a factor of 2 resulting in 64 x 64 pixel images with 4.48 Å/pixel. The particle stack 
was reference-free aligned by rotation and translation operations and the images were 
grouped into 50 classes by K-means classification (Penczek et al., 1992). Because no 
3D reference was available for mTLR225-587/Fab, the high quality class averages with 
sharp particle boundary and flat background were used for 3D modeling of the 
mTLR225-587/Fab complex in PyMOL (Schrödinger, USA) by arranging the crystal 
structures of mTLR2 (PDB code 2Z81) (Jin et al. 2007) and an IgG4 antibody Fab 
fragment (PDB code 2NY7) (Zhou et al., 2007) to match the particle shape seen in the 
averages. The resolution of the model was truncated to 30 Å and used as a first 
reference for single-particle reconstruction using the reference-based alignment method 
in SPIDER (Shaikh et al., 2008a). Reference projections were created from the 3D 
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reference, and the obtained alignment parameters (shifts and rotations) were applied on 
the particle stack by alignment of the particles against the 2D references. An initial 3D 
reconstruction was computed from the aligned particle images. 39 iterations of back-
projections and angular refinement were performed in SPIDER to improve the density 
map. The aligned particles of a given reference view were displayed to control the 
distribution of particles among projections. The 3D reconstruction resolution was 
calculated by splitting the particle data into two equal sets prior to the back-projection 
procedure and comparison of the two resulting half-reconstructions. Using the Fourier 
shell correlation (FSC) = 0.5 criteria (Shaikh et al., 2008b), the resolution was 
calculated from the FSC curve of the final density map. Density map visualization, 
docking of the crystal structures and the Fab 3D model, and image preparation were 
performed using the Chimera software (Goddard et al., 2007; Pettersen et al., 2004). 
 
IIB.12 Crystallization of mTLR225-587/Fab 
IIB.12.1 Screening for suitable crystallization conditions 
Initial crystallization setups were carried out using commercial screens (Qiagen, Hilden, 
Germany) in 96-well sitting-drop plates. 400 nL drops composed of equal amounts of 
protein- and crystallization solution were pipetted using a Mosquito 4B nanolitre 
pipetting robot (TTP LabTech, UK). Plates were incubated at constant temperatures 
(4 °C, 16 °C and 20 °C). To produce crystals suitable for X-ray diffraction experiments, 
extensive optimization of initial hit conditions was performed manually in 24-well 
hanging drop formats using drop volumes of 2 µL by varying the physico-chemical 
parameters such as precipitant and protein concentration, ionic strength and 
temperature. Also, additive screening (Hampton Research, California, USA), variation 
of protein/reservoir ratio and adding of 1.5 % - 3 % glycerol was performed. 
 
IIB.12.2 Data collection and evaluation 
Single protein crystals were harvested from their mother liquor, briefly transferred to 
30 % glycerol cryoprotectant solution and flash-cooled in liquid N2. X-ray diffraction 
data set for mTLR2/Fab was collected at λ = 1.54 Å on a home source rotating anode 
(MicroMax-007HF generator; Rigaku, Japan) using a Saturn 944HG CCD detector 
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(Rigaku, Japan). Denzo and Scalepack of HKL3000beta suite (Minor et al., 2006; 
Otwinowski and Minor, 1997) and the CCP4 software suite (Collaborative 
Computational Project Number 4, 1994) were used for data processing. Molecular 
replacement trials were done with PHASER (McCoy et al., 2007) and MOLREP (Vagin 
and Teplyakov, 2010) using search models from OPN-305 Fab (with and without 
CDRs, see  IIB.10) and mTLR2 ECD (Jin et al. 2007) (with and without hagfish 
domain). 
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IIC Producing mouse/human Toll-like receptors 2 and 6 in 
insect cells using the baculovirus expression system 
IIC.1 Cloning 
The Fc gene was amplified by polymerase chain reaction (PCR) from the plasmid 
pCMV-hFc-XP (in-house plasmid) using primers with BglII, NdeI, NheI and HindIII 
restriction sites, and a TEV site N-terminal to the Fc fragment (Figure  IIC-1, A): 
Forward Primer:  
 BglII      NdeI      NheI       TEV          Fc 
5’ AAGGAGATCTCATATGACCATGGATGATGCTAGCGAGAATCTTTATTTTCAGGGCCCCAAATCTTGT GACAAAACTCAC 3’ 
 
Reverse Primer: 
 HindIII         Fc 
5’ AGGAGAAGCTTGCGGCCGCTCATTATCTAGATCATTTACCCGGGGACAGGGAGAGGC 3’ 
 
The amplified fragment was digested with BglII/HindIII and cloned into the expression 
vector pFastbac1 (pFB, Invitrogen) between BamHI and HindIII (BglII and BamHI 
have compatible cohesive ends) yielding the plasmid pFB-TEV-hFc. The gene construct 
gp67-hTLR632-585-His8 (synthesized by Geneart, Regensburg, Germany) was then 
cloned into pFB-TEV-hFc between the restriction sites NdeI and NheI resulting in the 
final plasmid pFB-gp67-hTLR632-585-His8-TEV-hFc. BamHI and XhoI restriction sites 
allow the facile removal of hTLR6 ECD from the construct to be replaced by gene 
constructs for hTLR219-588, mTLR225-587 and mTLR628-584 amplified from cDNA 
(purchased from ImaGenes, Nottingham, UK). The following PCR primers were used: 
hTLR219-588: 
              BamHI 
Forward Primer: GAGGAGGATCCAAGGAAGAATCCTCCAATCAGGC 
            XhoI 
Reverse Primer: AAGGTCACTCGAGTGTCCTGTGACATTCCGACACCGAG 
 
mTLR225-587: 
                 BglII 
Forward Primer: GAGGAGAGATCTCAGGAGTCTCTGTCATGTGATGCTTCTG 
                    XhoI 
Reverse Primer: AAGGTCACTCGAGCTGGTGACATTCCAAGACGGAGGG 
 
mTLR628-584: 
              BamHI 
Forward Primer: GAGGAGGATCCTCCTCTAATGAACTTGAGTCTATGGTAGA 
                    XhoI 
Reverse Primer: AAGGTCACTCGAGAGTATCACAGGACAGTGGAGACATGTG 
Material and Methods 44 
 
Figure  IIC-1 Cloning strategy to create the four pFB TLR plasmids 
(A) PCR from the plasmid pCMV-hFc-XP using primers with flanked BglII and HindIII restriction sites 
(red), the restriction sites NheI and NdeI (pink), and the TEV cleavage site yields the fragment TEV-hFc. 
(B) TEV-hFc was cloned into the vector pFB between BamHI and HindIII. BglII and BamHI are 
compatible restriction sites. This yields the plasmid pFB-TEV-hFc with introduced NdeI / NheI sites. (C) 
The synthesized DNA fragment gp67-hTLR6 ECD was cloned into pFB-TEV-hFc between NdeI and 
NheI yielding the first of the four final pFB-TLR plasmids. The introduced BamHI and XhoI restriction 
sites further allows a replacement of the hTLR6 ECD. (D) PCR fragments from genomic cDNA of 
mTLR2, mTLR6 and hTLR2 were cloned between BamHI and XhoI to form the other three pFB-TLR 
plasmids. Amp(R) / Gm(R) / Nm(R) = ampicillin/gentamicin/neomycin resistance; PH promoter = 
polyhedrin promoter for baculovirus expression; Tn7L / Tn7R = sites for site-specific transposition into 
baculovirus DNA. 
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The PCR products were cloned into pFB-gp67-hTLR632-585-His8-TEV-hFc replacing 
hTLR632-585 by using the restriction enzyme combinations BglII/XhoI and BamHI/XhoI.  
All DNA samples were purified using the GeneJET DNA Purification Kit or GeneJET 
Gel Extraction Kit (Fermentas) prior to ligation and the products of individual cloning 
steps were analyzed by agarose gel electrophoresis. The recombinant plasmids were 
verified by sequencing (Eurofins MWG Operon, Ebersberg, Germany). 
 
IIC.2 Baculovirus expression system 
IIC.2.1 Generation of recombinant Bacmid-DNA 
1 ng DNA of each recombinant pFastbac plasmid was transformed into chemical 
competent DH10Bac cells (Invitrogen, Carlsbad, USA). Within these cells the gene 
construct was to be integrated into the baculovirus mini-attTn7 site by site-specific 
transposition. The cells were plated on LBBac agar plates containing 100 µg/mL 
ampicillin, 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 µg/ml tetracycline, 100 µg/ml 
Bluo-gal, and 40 µg/mL IPTG. After incubating for 24 h at 37 °C and 24 h at room 
temperature (RT), large white colonies were picked and restreaked on fresh LBBac plates 
to confirm the white phenotype. The recombinant bacmid DNA was isolated according 
to the protocol in the BAC-TO-BAC® System manual (Invitrogen) and the gene inserts 
identified by PCR using the primers M13 Forward and M13 Reverse (Invitrogen) 
flanking the mini-attTn7 site following agarose gel electrophoresis of the PCR products. 
 
IIC.2.2 Cell counting 
Prior to cell seeding, the cell density of Sf21 cells per mL cell culture was calculated 
using a hemocytometer by counting the number of cells of four 1mm2 squares. To 
monitor the cell progeny and vitality during virus and protein production, manual 
counting with a hemocytometer as well as automated cell counting using a CASY 
counter (Roche Innovatis, Basel, Switzerland) was utilized to promote maximum 
accuracy. CASY counter further allowed the determination of cell diameters, an indirect 
measure for the virus concentration in the cells. 
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IIC.2.3 Transfection of bacmid DNA and virus production 
5 µL bacmid DNA (~400 ng/µL) were transfected into 1x106 seeded Sf21 cells grown 
in 2 mL ExCell medium using 5.5 µg Superfectin (Invitrogen). After 3 days of 
incubation in a 27 °C humidified incubator the supernatant containing the replicated 
virus was harvested. 2 mL of fresh ExCell medium was added and the cells incubated 
for another 48 h. The supernatant was pooled with the first harvest and the virus titer 
determined performing viral plaque assays.  
 
IIC.2.4 Plaque assay 
1.25x106 cells in 2 mL ExCell medium were seeded per well. After adhesion, the 
medium was removed and 500 µL of virus dilution (10-4, 10-5, 10-6) were immediately 
added to the cells. After 2 h incubation at 27 °C the virus supernatant was removed and 
the cells overlaid with 4 % agarose. The cells were incubated for 5 days upside down in 
a 27 °C humidified incubator. The cells were stained with neutral red solution for 4 h at 
27 °C, the solution was removed and the cells further incubated over night at RT in dark 
environment. The next day the white plaques were counted and the pfu/mL (plaque 
forming units per mL = viruses per mL) were calculated by including plaque number, 
virus volume and dilution factor. As positive control a commercial virus (Toshi virus) 
with known virus titer was used. 
 
IIC.2.5 Virus amplification 
The virus was amplified in several cycles repeating cell infection with virus (MOI = 
0.1-0.5), incubation, harvest of viruses, and plaque assay, to a volume of 800 mL virus 
solution with a virus concentration of 1x107 pfu/mL. The cell density and vitality was 
monitored in all steps by cell counting using a hemocytometer under the light 
microscope and by using a CASY Cell Counter. 
 
IIC.3 Expression and purification of (m/h)TLR(2/6)-His-Fc 
Protein expression was performed by infection of insect cells (1 x 106 cells/mL culture) 
with TLR-containing baculovirus using a MOI of 2. After 72 h the cells were harvested. 
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Determination of intracellular and extracellular protein portions was achieved using the 
Cytobuster protein extraction reagent (Merck, Darmstadt, Germany). The insect cells 
were centrifuged and the supernatant was collected. The protein supernatant was 
dialyzed against equilibration buffer (50 mM Tris pH 8, 150 mM NaCl, 1 mM DTT, 
0.5 mM EDTA) for 24 h and then coupled to Protein A sepharose matrix (GE 
Healthcare). The column was washed with equilibration buffer and the protein-coupled 
matrix was incubated with TEV protease at 4 °C over night, following incubation at 
room temperature for 4 h. To elute the protein prior to protease digestion, the protein 
was rapidly eluted with glycine buffer pH 3 and the drops were immediately collected in 
100 mM Tris pH 8.0, 100 mM NaCl, but which could not successfully refold the 
protein. 
 
IIC.4 Western blotting 
Protein bands from SDS-PAGE gels were transferred to PVDF membrane (immobilon-
P, Millipore, Massachusetts, USA) for subsequent immunodetection using a Semi-Dry 
Transfer Cell (BioRad, California, USA). Freshly run SDS-PAGE gel and blotting 
paper were equilibrated for 15 in transfer buffer. The PVDF membrane was equilibrated 
in 100 % methanol for 5 sec following washing in H2O for 5 min and in transfer buffer 
for 10 min. For the transfer the gel was placed onto the membrane and both was placed 
between two layers of blotting paper onto the anode of the semi-dry transfer cell. The 
Western blot was run with 15 V for 30 min. To prevent non-specific binding blocking 
of the membrane was achieved by incubation for 1 h with 50 mL of TBST buffer 
following washing for 3 x 5 min in TBST buffer. The primary antibody was incubated 
with the membrane for 1 h at RT. The membrane was again washed 3 x 5 min with 
TBST buffer. The membrane was then incubated with an alkaline phosphatase (AP)-
conjugated antibody for 1 h at RT and washed 2 x 5 min in TBST buffer. For 
immunoblotting of (m/h)TLR(2/6)-His-Fc, a mouse anti-His-tag antibody was used as 
primary antibody and an AP-conjugated anti-mouse antibody as secondary antibody. To 
label the Fc-tag within the TLR constructs, a primary AP-conjugated goat anti-human 
antibody was used, which detects the heavy chain as well as the light chain of human 
IgG antibodies. Prior to staining reaction, the membranes were equilibrated for 5 min in 
AP buffer. The enzymatic staining reaction was started by incubation for 1 to 5 min 
with a mixture of 10 mL AP buffer, 66 µL NBT and 33 µL BCIP. The staining was 
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stopped with several solution changes with deionized water and drying of the 
membrane. 
Transfer buffer:  6 g Tris-Base 
    72 g glycine 
    300 mL methanol 
    Filling up to 2 L with H2O 
 
TBST wash buffer:  20 mL of 1 M Tris, pH 8 
    37.5 mL of 4 M NaCl 
    0.5 mL Tween-20 
    Filling up to 1 L with H2O 
 
AP buffer:   100 mL of 1 M Tris, pH 9.5 
    25 mL of 4 M NaCl 
    10 mL of 0.5 M MgCl2 
    Filling up to 1 L with H2O 
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III Results 
IIIA Inhibition of mTLR2 with a monoclonal antibody 
The antibody used in these studies, the monoclonal anti-human/mouse TLR2 antibody 
OPN-305 (Opsona Therapeutics, Dublin, Ireland) is a humanized version of the murine 
anti-human/mouse TLR2 antibody OPN-301, first developed by Prof. Dr. Carsten 
Kirschning (Universitätsklinikum Essen, Germany) as antibody T2.5. OPN-305 was 
provided by Opsona in 10 mg/mL stocks in 25 mM sodium citrate pH 4.5 and 125 mM 
NaCl. The antibody was shock frozen in liquid N2 and stored at -80 °C until usage. 
The mTLR2 clone was initially isolated by Prof. Dr. Carsten Kirschning for expression 
of mTLR2 in HEK293 cells (Meng et al., 2004), and later recloned into a pFastbac 
vector by Ute Widow (HZI, Braunschweig, Germany) for the expression in insect cells. 
A His6-tag was added to the C-terminus. The protein production was performed by the 
group of Dr. Joop van den Heuvel (HZI, Braunschweig, Germany) and shipped on ice to 
South Africa. The protein was produced in 6 L Sf21 insect cell cultures as well as in a 
35 L fermenter in CHO lec3.2.8.1 cells, optimized for the production of glycoproteins 
for structural analysis (Stanley, 1989; Wilke et al., 2010).  
 
 
Figure  IIIA-1 Schematic representation of mTLR225-587-His6 
The ECD mTLR225-587 is C-terminally linked to a His6-tag. The molecular weight of the recombinant 
protein is 64 kDa. 
 
IIIA.1 Complexation of TLR2 and OPN-305 
IIIA.1.1 Purification of mTLR225-587-His6 
For simplicity, the His6-tagged ECD of murine TLR2, mTLR225-587-His, will henceforth 
be referred to as TLR2 or mTLR2 in all sections of chapter IIIA.  
The C-terminal His6-tag attached to TLR2 allows initial purification by Ni-NTA affinity 
chromatography (AC), followed by anion exchange chromatography (AEC). TLR2 
protein charges from insect cells and CHO cells were indistinguishable in all 
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chromatographic purification steps. The quality of the purification was analyzed by 
SDS-PAGE (Figure  IIIA-2). 
 
 
 
Figure  IIIA-2 Purification of TLR2 by Ni-NTA affinity chromatography 
SDS-PAGE of samples of the flow through (FT); wash fractions W1 (10 mM imidazole), W2 + W3 
(40 mM imidazole); elution fractions E1 + E2 (100 mM imidazole), E3 + E4 (250 mM imidazole), E5 
(500 mM imidazole), and matrix beads after elution (B). TLR2 eluted with buffers containing 100 mM 
and 250 mM imidazole. Gel marker: Unstained Protein Molecular Weight Marker (Fermentas). 
 
Coupling TLR2 to the Ni-NTA matrix allowed for the majority of impurities to be 
removed by washing with buffers containing 10 - 40 mM imidazole (Figure  IIIA-2, 
lanes W1 – W3). TLR2 was eluted with buffer containing 100 - 500 mM imidazole 
(Figure  IIIA-2, lanes E1 – E5). Only insignificant amounts of protein remained bound to 
the matrix (Figure  IIIA-2, lane B). The yield after Ni-NTA AC was generally 0.4 – 
0.5 mg TLR2 per L of insect cell culture and 0.6 mg per L CHO cell culture. 
The second step in purifying TLR2 involved AEC to remove remaining impurities 
(Figure  IIIA-2, lane E1). 
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Figure  IIIA-3 Purification of TLR2 by anion exchange chromatography 
Partially pure TLR2 from Ni-NTA AC was further purified by AEC. The proteins were eluted from the 
column according to their negative charge by applying a salt gradient from 8 mM to 200 mM NaCl (green 
line) and were monitored by measuring the absorption at 280 nm (orange curve). Elution fractions were 
analyzed by SDS-PAGE. Fractions from the main peak (green bar) were used for complexation with the 
OPN-305 Fab fragments. Gel marker: Unstained Protein Molecular Weight Marker (Fermentas). 
 
Applying a salt gradient to the AEC column resulted in TLR2 elution in the range of 
100 - 140 mM NaCl, reaching a maximum at 115 mM NaCl (Figure  IIIA-3). Elution 
occurs as one major and several smaller peaks of absorbance at 280 nm. Corresponding 
elution fractions were analyzed by SDS-PAGE identifying all fractions as TLR2. 
Impurities were not detectable. As the distinct peaks in the AEC may be due to different 
glycosylation states of TLR2, only the central fractions of the main peak (Figure  IIIA-3, 
green bar) were pooled and used for further experiments. 
 
IIIA.1.2 Deglycosylation of TLR2 
The ECD of mTLR2 is known to be glycosylated in three sites. Although glycosylation 
is already minimized in Sf21 insect cells and especially in the CHO strain used here 
resulting in shorter and more homogeneous sugar chains, glycosylation variability can 
still introduce protein heterogeneity interfering with crystallization. 
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We therefore chose to deglycosylate TLR2 with PNGase F (New England Biolabs, 
Massachusetts, USA), an amidase that cleaves the bond between the asparagine residues 
and the first GlcNAc in N-linked glycoproteins (Maley et al., 1989).  
The following SDS gel documents TLR2 deglycosylation using two enzyme 
concentrations and a range of incubation times (Figure  IIIA-4). 
 
Figure  IIIA-4 Deglycosylation of TLR2 
11 µg of TLR2 were incubated with 5 u and 50 u PNGase F for 1 h, 2 h, 4 h, 6 h, and 20 h at RT. The 
reaction was stopped by adding SDS buffer and denaturation of the samples at 95 °C. The samples were 
analyzed by SDS-PAGE. Controls without enzyme were analyzed before start (0 h) at 4 °C and after 20 h 
at RT. Gel marker: Unstained Protein Molecular Weight Marker (Fermentas). 
 
11 µg of TLR2 was fully deglycosylated after 1 h incubation with 50 u PNGase F. 
However, 6 h to 20 h were necessary to deglycosylate TLR2 using only 5 u PNGase F. 
No degradation of TLR2 is apparent after 20 h at room temperature (RT). 
Deglycosylating TLR2 from both insect as well CHO cells indicate that actual 
deglycosylation in the form of changed mass as judged by SDS-PAGE (Figure  IIIA-4) 
is only apparent in TLR2 from insect cells. The mass difference between glycoproteins 
from CHO cells and their deglycosylated counterparts is too small to see in SDS-PAGE. 
Surprisingly, glycosylated and deglycosylated TLR2 are indistinguishable in AEC. 
Following the analysis in Figure  IIIA-4, 10 u of PNGase F were used per 10 µg of 
TLR2 protein and incubation was extended to 15 h at RT in preparative 
deglycosylation. Glycosylated as well as deglycosylated TLR2 was used for Fab 
complex formation and crystallization studies. 
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IIIA.1.3 Generation and purification of OPN-305 Fab fragments 
The two heavy and two light chains constituting an antibody come together to create 
three roughly similarly sized protein domains: two identical Fab and one Fc domain. 
Only the Fab fragments bear the variable regions consisting of the CDRs responsible for 
antigen recognition. Hence the antibody OPN-305 was digested with the enzyme 
papain, a cysteine protease to cleave the antibody N-terminally of the two disulfide 
bridges connecting the two heavy chains. This yields two Fab and one Fc domains 
(Figure  IIIA-5). The smaller Fab fragment is preferred over the full length antibody for 
structural studies. This is because it potentially forms a rigid 1:1 complex with TLR2 
whereas the uncleaved antibody would bind two TLR molecules and be highly flexible 
due to flexible linkers between the three domains. The flexibility could introduce 
protein heterogeneity, a major obstacle to crystallization and EM. 
 
Figure  IIIA-5 Papain cleavage of antibodies 
Antibody OPN-305 has two papain cleavage sites, one in each of the equivalent heavy chain (scissor 
symbols). Digestion releases two Fab fragments (48 kDa each) and one Fc fragment (54 kDa). 
 
After proteolytic cleavage, size-exclusion chromatography (SEC) was used to separate 
the Fab and Fc fragments (~50 kDa) from the uncleaved (~150 kDa) and incompletely 
cleaved (~100 kDa) antibody molecules (Figure  IIIA-6 A). Protein fractions from the 
SEC (Figure  IIIA-6 A, green and red bars) were analyzed by SDS-PAGE to confirm the 
purity of the samples (Figure  IIIA-6 B).  
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Figure  IIIA-6 Separation and analysis of antibody fragments after papain cleavage 
(A) OPN-305 was digested with papain and the products separated by SEC. Fractions marked by bars 
were analyzed by SDS-PAGE. (B) SDS gel of completely (green bar) and incompletely cleaved 
antibodies (orange bar). Fractions marked by a yellow bar were pooled and separated in a second SEC. 
(C) SDS-PAGE analysis of fractions of the second SEC. The marked samples (yellow bar) were pooled 
and used for further experiments. Gel marker: Unstained Protein Molecular Weight Marker (Fermentas). 
 
Non-reducing sample conditions were used to avoid breaking disulfide bridges linking 
heavy and light chains allowing the full size of fragments to be analyzed. The singly or 
incompletely cleaved antibody retains a mass of ~100 kDa and runs on the SDS gel 
above the 116 kDa marker band (Figure  IIIA-6 B, red bar) presumably due to its 
elongated shape. For Fab/Fc mixtures SDS-PAGE should, in principle, reveal two 
closely positioned bands of ~50 kDa, with the Fc fragment (54 kDa) running slightly 
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higher than the Fab fraction (48 kDa). Instead four bands are observed (Figure  IIIA-6 B, 
green bar), suggesting that papain cleaves the antibody at two distinct positions. As 
protein crystallization requires homogenous Fab fragments, the SEC fractions bearing 
the two Fab variants (the two lower bands in Figure  IIIA-6 B, yellow bar) were pooled 
and run on a second SEC. Its fractions were again analyzed by SDS-PAGE (Figure 
 IIIA-6 C). Only those fractions predominantly composed of the smaller Fab variant 
were pooled and used for further experiments (Figure  IIIA-6 C, yellow bar). Around 
80 % of the larger Fab variant could be removed. 
Mass spectrometry was used to determine the precise mass of the two Fab variants. 
 
IIIA.1.4 Identification of Fab fragments by mass spectrometry 
Peptide mass fingerprinting was used on SDS gel samples of the larger and smaller Fab 
fragment. In both cases, peptides of the constant Fab region of light chain (Ig kappa 
chain C, Uniprot entry: P01834) and heavy chain (Ig gamma-4 chain C, Uniprot entry: 
P01861) of human IgG4 antibodies were identified (Figure  IIIA-7). 
 
Figure  IIIA-7 Mass spectrometry of Fab 
Electrospray ionization mass spectrometry of Fab in solution: two Fab variants of different sizes (47021 
Da and 47457 Da) were identified. Insert: The sample was analyzed by SDS-PAGE prior to MS, 
confirming two distinct Fab sizes. Gel marker: Unstained Protein Molecular Weight Marker (Fermentas). 
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Electrospray ionization mass spectrometry (ESI-MS) was used to determine the exact 
molecular mass of the fragments in solution. Two proteins of mass 47021 and 47457 Da 
were identified (Figure  IIIA-7). Employing the known amino acid sequences of light 
chain (Fablight) and heavy chain (Fabheavy) of OPN-305 the two papain cleavage sites in 
the heavy chain were calculated. A mass of 47457 Da corresponds to Fablight + Fabheavy 
Q1-G221, whereas the 436 Da shorter variant matches with Fablight + Fabheavy Q1-G217. 
The calculation and heavy chain sequence is shown in Figure  IIIA-8. 
 
 
Figure  IIIA-8 Fab heavy chain C-termini 
(A) Calculation of molecular weights of the two possible Fab variants according to their masses 
determined by MS. (B) Amino acid sequence of Fab heavy chain. The two papain-derived C-termini are 
marked by arrows. The two disulfide bridges downstream of the cleavage sites are highlighted in red. 
 
The peak heights or signal intensities of the ESI-MS experiment (Figure  IIIA-7) 
indicates the shorter Fab fragment (Fablight/Fabheavy Q1-E217) constitutes ~15 % and the 
larger (Fablight/Fabheavy Q1-G221) ~85 % of the sample. 
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IIIA.1.5 Generation and purification of the TLR2/Fab complex 
Purified TLR2 and Fab were incubated in a molar ratio of 1:2 and analyzed by SEC 
(Figure  IIIA-9). 
 
Figure  IIIA-9 Peak shift during SEC between TLR2 and TLR2/Fab 
Overlay of size exclusion chromatographs of TLR2/Fab (green) and TLR2 (orange). Peak shift indicates 
complex formation. Fractions of the green curve were analyzed by SDS-PAGE. TLR2/Fab complex 
fractions (blue bar) and excess Fab (ochre bar) are marked. Sample of TLR2 and non-reduced sample of 
TLR2/Fab (R) are shown for comparison. Gel marker: Unstained Protein Molecular Weight Marker 
(Fermentas). 
 
The overlay of TLR2/Fab SEC (Figure  IIIA-9, green curve) with a curve of TLR2 
without Fab (Figure  IIIA-9, orange curve) shows a clear peak shift indicating the 
generation of the complex, which has a higher molecular weight than TLR2 alone. The 
applied TLR2 was completely bound to Fab molecules in a 1:1 complex, excess Fab 
fragments and residual Fc fragments could be separated. The SEC fractions were 
analyzed by SDS-PAGE. Fractions of the complex peak (Figure  IIIA-9, blue bar) show 
two peaks on the gel (upper band is TLR2, lower band is Fab under non-reduced 
conditions), whereas the excess Fab peak (Figure  IIIA-9, ochre bar) resulted in a single 
band. For comparison, the SDS-gel also shows a sample of TLR2 (first lane) and of the 
complex under reduced conditions (second lane), leading to the separation of Fab into 
two chains about 25 kDa. 
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IIIA.1.6 Native PAGE of the complex 
To verify the complex formation, native PAGE was performed, which allows the 
analysis of proteins in their folded, non-denatured form. In native PAGE, the gel 
mobility depends on the ratio of electric charge to hydrodynamic friction (Arakawa et 
al., 2006). Thus, two proteins with different sizes and shapes like TLR2 and TLR2/Fab 
are expected to migrate differently through the gel. 
 
Figure  IIIA-10 Native PAGE analysis of TLR2/Fab 
Comparison of TLR2 monomer with TLR2/Fab under native conditions. The complex migrated slower 
through the pores of the gel due to its size. 
 
As seen in Figure  IIIA-10, the migration path of the complex is shorter than that of the 
TLR2 monomer, which confirms that the TLR2/Fab complex was successfully 
generated. The fact that the complex remains stable during the PAGE run is an 
indication of high affinity of Fab towards TLR2. 
 
IIIA.1.7 Stability of TLR2/Fab 
The quality of the TLR2/Fab complex was further analyzed by anion exchange 
chromatography (AEC). The aim was to establish whether the complex binds uniformly 
to the AEC column or if a distribution of peaks would be observed, indicating an 
instable or flexible protein complex. 
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Figure  IIIA-11 Anion exchange chromatography of TLR2/Fab 
TLR2/Fab from the SEC was separated by AEC. The proteins were eluted from column dependent by 
their negative charge by applying a salt gradient from 0 mM to 200 mM NaCl (green line) and were 
monitored by measuring the absorption at 280 nm (orange curve). 
 
The chromatogram in Figure  IIIA-11 shows a homogeneous and sharp peak eluting with 
buffer containing 120 mM NaCl. Only a small shoulder can be observed at 140 mM 
salt. The elution time of the main peak and the shoulder is similar to that of the AEC of 
the TLR2 monomer (Figure  IIIA-3), indicating that TLR2/Fab and the TLR2 from the 
fractions which were chosen initially in  IIIA.1.1 show a similar binding behavior to the 
chromatographic column, and that the protein has not changed in terms of stability and 
folding. For further experiments, the purified complex after SEC was used. Selecting 
the correct TLR2 fractions after AEC (Figure  IIIA-3) while excluding neighboring 
peaks proved critical in obtaining homogenous TLR2, and thus, TLR2/Fab. 
 
IIIA.2 Negative stain electron microscopy 
Electron microscopy (EM) is a commonly used technique to visualize a wide range of 
biological and inorganic specimens including macromolecules like proteins and protein 
complexes. In contrast to crystallography, EM is a “direct” method of observing 
molecules. In negative stain EM, the sample is deposited on a carbon coated grid and 
then covered with a small drop of an electron-opaque staining solution. The stain fixes 
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the specimen on the grid in random orientations and produces high contrast ‘electron 
micrographs’, images of a field of the specimen. By collecting thousands of particle 
images, a single-particle reconstruction may be attempted to obtain a representation of 
the outer surface of the molecule. If, as in this case, crystal structures of the individual 
molecules of a complex have been solved, it may be possible to dock these structures 
into the EM density map allowing their mode of interaction to be studied. 
 
IIIA.2.1 Visualization of TLR2/Fab by negative stain EM 
After the TLR2/Fab complex was formed and purified as described above, the sample 
was directly used in negative stain EM experiments. A sample with a concentration of 
39 nM was deposited on carbon-coated glow-discharged grids and stained with uranyl 
acetate solution (see Material and Methods,  IIB.11.1.). 
 
Figure  IIIA-12 Negative stain EM imaging of TLR2 and TLR2/Fab 
Visualization of (A) TLR2 and (B) TLR2/Fab complex by negative stain EM. Representative particles are 
highlighted by circles. TLR2 particles (A) have the characteristic horseshoe-like shape, clearly 
distinguishable from the TLR2/Fab particles (B). Scale bar is 20 nm. 
 
The particles on the negative stain EM images have a homogenous shape with a length 
of ~150 Ǻ and a width of ~100 Å (Figure  IIIA-12, B). The TLR2/Fab particles can be 
clearly distinguished from EM particles of TLR2, which reveal the characteristic 
horseshoe-like shape (Figure  IIIA-12, A). 
 
In addition to negative stain EM, attempts were made to collect images of TLR2/Fab by 
cryo-EM. For that purpose different dilutions of protein sample (614 nM, 245 nM, 
123 nM and 61 nm) were deposited on carbon coated as well as non-carbon grids. 
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Several images were collected from different areas of the grids. However, the size of 
TLR2/Fab of 117 kDa was below the visible limit of cryo-EM and no particles could be 
observed on the images. 
 
IIIA.2.2 Particle classification and averaging 
Reconstructing a 3D density map involves a number of steps. First, a large stack of 
particle images need to be collected representing random orientations of the target 
molecule. Here, a total of 5174 such “particles” were picked from many hundred EM 
images using the sparx engine (Hohn et al., 2007). Mathematical operations were 
carried out with the software SPIDER (Frank et al., 1981; Frank et al., 1996) to align 
the particles by reference-free alignment (Penczek et al., 1992) and to classify the 
particles into 50 classes with largely identical views. Averages of these classes were 
then computed to generate high-contrast particle representations. The class averages are 
shown in Figure  IIIA-13. 
 
 
Figure  IIIA-13 Class averages 
5174 particles were classified into 50 classes with largely identical views by mathematical operations 
using the software SPIDER. The classes were averaged to obtain high quality particle representations. 
 
The averages depict the TLR2/Fab complex in different orientations. Many averages 
appear similar indicating a majority of particles to have been fixed to the grids in a 
preferred orientation. Nevertheless, distinct variation is apparent, a prerequisite for a 
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successful 3D reconstruction. Most averages have a sharp particle boundary and flat 
background indicating high consistency of particles within the class.  
 
IIIA.2.3 Reconstruction of the 3D density map 
The best class averages were used to manually construct a first 3D model of TLR2/Fab 
in PyMOL (Schrödinger, USA) by placing the crystal structures of mTLR2 (PDB code 
2Z81) (Jin et al., 2007) and an IgG4 antibody Fab fragment (PDB code 2NY7) (Zhou et 
al., 2007) in contact with each other according indicated by the particle shape in the 
averages. This model was used as a reference for single-particle reconstruction using the 
reference-based alignment method (Shaikh et al., 2008a). First, a set of 86 2D reference 
projections was generated from the 3D reference model. The particle stack was then 
assigned to the 2D projections applying rotations and translations as required. The 
aligned particle images were used to create an initial 3D reconstruction, of which 86 
reference projections were again generated. In total 39 iterations of back-projections 
were performed to refine all alignment parameters (Figure  IIIA-14).  
 
 
Figure  IIIA-14 Reference-based alignment method 
Reference-projections and particle alignment corresponding to the 39th round of back-projection. The first 
row depicts 12 of the 86 2D reference projections generated from the previous iteration. Rows 2-6 are 
individual particles of this class aligned to their reference in the first line. After alignment, each particle 
set of a reference was averaged, as shown in the last row. 
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Comparing the reference-projections with the particle averages reveals a high degree of 
consistency supporting the correctness of the projections and the high quality of 
alignment. 
The back-projection method resulted in the 3D density map presented in Figure  IIIA-15. 
 
 
Figure  IIIA-15 3D density map of TLR2/Fab filtered to 21.7 Å 
The density map is rotated about the vertical axis in 60° steps or about 120° and 60° around the horizontal 
axis relative to the central representation, with rotations indicated around the axis of rotation (circular 
arrows). The complex structure consists of a horseshoe-like domain and an elongated domain attached 
laterally to the center of the “horseshoe” extending away from the latter. Scale bar is 50 Å. 
 
To calculate the resolution of the 3D reconstruction, the particle data was split into two 
equal sets prior to the back-projection procedure and the two resulting half-
reconstruction compared. Using the Fourier shell correlation (FSC) = 0.5 criteria, a 
resolution of 21.7 Ǻ was calculated from the FSC curve of the final density map 
(Shaikh et al., 2008b). 
The structure of the complex is ~130 Å x 90 Å x 70 Å in size and composed of a nearly 
planar horseshoe-like domain on which a second domain is laterally positioned near its 
central region. The latter forms angles of 15° and 40° relative to the perpendicular 
bisector of the horseshoe when respectively projected onto the horseshoe plane or the 
perpendicular plane sharing the bisector. 
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IIIA.3 Analysis of TLR2/OPN-305 interaction 
IIIA.3.1 Modeling of the Fab domain 
Antibody Fab fragments are composed of two polypeptide chains, a partial “heavy” and 
the complete “light” chain of its parent antibody. Each chain bears a constant and a 
variable part. Although the crystal structure of OPN-305 has not previously been 
solved, antibodies are mostly largely identical in structure, except for the 6 
complementarity determining regions (CDRs) responsible for antigen recognition. 
Structure-based modeling using the online server Swiss-Model was used to generate the 
variable domain of OPN-305 (see Material and Methods,  IIB.10), in particular so as to 
obtain a structure with correct CDR sequences and lengths. Quality estimation indicates 
a model of high reliability giving global QMEAN4 scores of 0.685 for Fab light chain 
and of 0.818 for Fab heavy chain (quality estimate ranges between 0 and 1 with higher 
values for better models). The QMEAN4 Z-scores comparing the model with the scores 
of reference X-ray structures resulted in values close to zero, with -1.19 for Fab light 
chain and 0.14 for Fab heavy chain, respectively (in theory, models of low quality are 
expected to have strongly negative QMEAN4 Z-scores).    
 
Figure  IIIA-16 Local model quality estimation of Fab variable domain 
Anolea and Qmean scores of (A) the light chain and (B) heavy chain of OPN-305 Fab variable domain. 
The CDRs are indicated by orange lines and named L1-L3 for the three CDRs of the light chain and H1-
H3 for the three CDRs of the heavy chain. For a detailed description see the text below. 
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As expected the local scores for individual amino acid residues reveal the highest 
structural uncertainty in areas of the CDRs (Figure  IIIA-16). Within the light chain the 
Anolea score shows three regions with slightly positive values (in red), all of which 
belong to the CDRs (Figure  IIIA-16, A). The Anolea score of the heavy chain exhibit 
four regions with modest positive values, of which three belong to the CDRs (Figure 
 IIIA-16, B). Negative energy values (in green) represent a favorable energy 
environment whereas positive values (in red) an unfavorable energy environment for a 
given amino acid. The Qmean score is an estimate of the expected structural inaccuracy at 
a given position with small values corresponding to regions in the model being 
potentially more reliable. The local scores show modest higher values in particular 
within the CDR regions. The weakest model reliability is expected for CDR H3 of the 
heavy chain. 
The crystal structure of an IgG4 antibody with identical constant domain sequence as 
OPN-305 was used as a framework (PDB code 2NY7) (Zhou et al., 2007) and its 
variable domain replaced by that of the modeled OPN-305 variable domain.  
 
IIIA.3.2 Docking of TLR2/Fab into the EM density 
To identify the interaction area between TLR2 and OPN-305 Fab, crystal structures of 
mTLR2 and antibody were fitted into the EM density map using the automated “Fit into 
map” feature of modeling software Chimera (Figure  IIIA-17).  
 
Figure  IIIA-17 Representation of the complex molecules within the EM density map. 
The structure is rotated about the vertical axis in 45° steps. TLR2 is shown in green, Fab heavy chain in 
brown, and Fab light chain in blue. 
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The Fab domain model was placed into the EM map to match the lateral density 
structure emanating from the center of TLR2. The variable domain and its antigen 
binding site were oriented towards the TLR2 surface (Figure  IIIA-18, blue: light chain; 
brown: heavy chain). 
 
 
Figure  IIIA-18 Modeling OPN-305 Fab fragment into the EM-derived molecular surface 
The evolutionary homology of the Fab light and heavy chains results in an approximate two-fold 
rotational symmetry for all Fab fragments along their longest molecular axis. Fitting the generated Fab 
model structure into the EM-derived molecular surface therefore results in two orientations of Fab related 
by a 180° rotation around the vertical axis. The two orientations are here denoted Fab#1 (A) and Fab#2 
(B). The Fab heavy and light chains are respectively rendered in brown and blue. Comparing the two 
orientations reveals a better agreement between structural model and EM molecular surface for Fab#2 (B) 
as compared to Fab#1. The latter results in more clashes (red squares) between model and EM surface, 
implying Fab#2 to be the more likely orientation for the OPN-305 Fab fragment. 
 
Heavy and light chains of Fab fragments are comparable in length and structure 
resulting in an approximate 2-fold rotational symmetry around the longest axis of the 
domain. Correspondingly, the OPN-305 Fab structural model has been modelled in two 
possible orientations (denoted Fab#1 and Fab#2) into the EM derived molecular 
surface. Comparing the two resulting models (Figure  IIIA-18) reveals that Fab#2 
(Figure  IIIA-18, B) conforms more closely with fine structure of the experimental 
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molecular surface than Fab#1 (Figure  IIIA-18, A). We therefore proposed that the 
orientation described by Fab#2 constitutes the more probable orientation. 
Like all TLRs, the ECD of mTLR2 is composed of multiple consecutive LRRs forming 
a solenoid structure, which is forced into a curved configuration because of closely 
packed β sheets on the concave surface and the larger helices on the convex side - 
generating a horseshoe-like shape (Botos et al., 2011; Kajava, 1998). Our 3D 
reconstruction shows a similar structural feature allowing the crystal structure of 
mTLR2 ECD (PDB code 2Z81) (Jin et al., 2007) to be placed into the curved structure 
of the EM map with a high degree of reliability. As TLR-ECDs are bent yet almost 
planar in shape, the N- and C-terminal halves of the domain are related to each other by 
an approximate two-fold rotational symmetry. Correspondingly, mTLR2 may be placed 
into the EM molecular surface in two essentially equivalent orientations here termed 
TLR#1 and TLR#2 (Figure  IIIA-19).  
 
 
 
Figure  IIIA-19 Modeling TLR2 into the EM-derived molecular surface 
The N- and C-terminal halves of the TLR2 ECD are related to each other by an approximate two-fold 
rotational symmetry, allowing the placement of the domain into the EM surface in two orientations. They 
are here denoted TLR#1 (A) and TLR#2 (B). Major clashes of the TLR2 surface with the volume surface 
can be observed in orientation #2 (B) in comparison to orientation #1 (A), highlighted by red squares, 
implying TLR#1 to be the more likely orientation for the TLR2 ECD. 
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In TLR#1, the surface area involved in dimerization with TLR1 and TLR6 faces the 
OPN-305 Fab fragment, whereas the dimerization site would face away from the Fab in 
TLR#2. Overall TLR#1 is found to result in fewer and less dramatic clashes between 
molecular model and the EM molecular surface (Figure  IIIA-19, A), whereas TLR#2 
reveals some major clashes as indicated by red squares (Figure  IIIA-19, B). Therefore, 
TLR#1 could be identified as the correct orientation in the TLR2/Fab complex. 
 
IIIA.3.3 OPN-305 blocks the TLR2 dimerization site 
After docking both TLR2 and Fab model structures into the EM density, the TLR2 part 
was superimposed on the TLR2 parts of the TLR2/TLR1 and TLR2/TLR6 complex 
crystal structures (Figure  IIIA-20). 
 
Figure  IIIA-20 TLR2 dimerization is blocked by OPN-305 
Superpositioning TLR2 of TLR2/OPN-305-Fab onto TLR2 parts of TLR2/TLR1 and TLR2/TLR6. The 
structure is rotated by 45° around the vertical and horizontal axes (relative to the structure on the left). 
TLR2 is shown in green, Fab heavy chain in brown, and Fab light chain in blue, TLR1 in violet, and 
TLR6 in red. 
 
The superpositioning clearly illustrates that OPN-305 covers a comparable epitope on 
TLR2 as TLR1 and TLR6 do. Clearly, OPN-305 blocks the TLR-TLR dimerization 
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interface on TLR2, preventing TLR1 and TLR6 from binding to TLR2 to generate an 
intracellular signal. 
 
IIIA.3.4 Analysis of the epitope 
The structural similarity of the Fab light and heavy chains results in an approximate 
2-fold rotational symmetry along the Fab longest axis and this symmetry is discernible 
in the EM-determined molecular surface. 
 
Figure  IIIA-21 Binding of Fab to TLR2 in two theoretical orientations 
Fab orientation #1 (A and C) and #2 (B and D) in two views. TLR2 is highlighted in green, the leucine 
rich repeats 11 to 14 of TLR2 in orange, the Fab heavy chain in brown, and the Fab light chain in blue. 
The six CDRs are coloured individually and are termed H1 – H3 (CDRs of the heavy chain) and L1 – L3 
(CDRs of the light chain). 
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The largest differences between light and heavy chain of a Fab fragment involves the 
six variable region CDRs, due to the unique sequence, length and conformation of each 
CDR.  
Although one of the two possible orientations of the Fab molecular model results in a 
better fit to the density (Figure  IIIA-18), both orientations were analyzed and compared 
to comprehensively analyze all possible molecular interactions (Figure  IIIA-21). 
Comparing the binding interface for both Fab rotations indicates that in both cases the 
CDRs of OPN-305 interact primarily with the lateral surface loops of LRRs 11-14. In 
particular, the extended loop of LLR11 is crucial for recognition, due to its proximity to 
at least 3 CDRs of heavy and light chain (Figure  IIIA-21). 
 
IIIA.3.5 TLR2 surface residues involved in Fab interaction 
The optimal molecular model derived from the EM molecular surface and the molecular 
models of the constituent proteins clearly identifies LRRs 11-14 as the dominant site of 
interaction between TLR2 and the antibody Fab fragment. Despite limitations imposed 
by the resolution (inherent to the EM method employed) in identifying residues 
involved in recognition, these residues additionally need to conform to two additional 
criteria allowing their identity to be narrowed down: 1) Their side chains must face the 
antibody and 2) the recognition residues of TLR2 should be (partly) conserved in 
TLR2s from different organisms with which the antibody is known to cross-react. 
In total, 10 amino acids on the surface of LRRs 11-14 fulfill the first requirement 
outlined above, based on the structure of mTLR2 (PDB code 2Z81). They include 
histidine 318, proline 320, glutamine 321 and tyrosine 323 in LRR11; lysine 347 and 
phenylalanine 349 in LRR12; leucine 371, glutamate 375 and tyrosine 376 in LRR13; 
and histidine 398 in LRR14 (Figure  IIIA-22). 
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Figure  IIIA-22 Exposed surface residues of mTLR2 involved in recognition by OPN-305 
Surface-exposed residues in LRRs 11-14 of TLR2 are rendered in grey and labeled in red. Ten residues 
were identified having the highest probability of being involved in antibody interaction. (A) Top view, 
(B) front view, (C) side view and (D) front view with Fab heavy chain (brown) and light chain (blue). 
 
Compliance of the second requirement outlined above, involving residues being 
conserved in TLR2s from different organisms, was investigated by multi-sequence 
alignment using the amino acid sequences of LRRs 11-14 from human, murine, apish 
and porcine TLR2. This analysis reveals that all residues listed above are perfectly 
conserved in all of these molecules, except glutamine 321 and tyrosine 323 (Figure 
 IIIA-23). Glutamine 321 is replaced by arginine in human TLR2 whereas tyrosine 323 
is replaced by phenylalanine in porcine TLR2. 
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Figure  IIIA-23 Multi-sequence alignment of LRRs 11-14 from different species 
OPN-305 neutralizes TLR2 from different mammals. The amino acid sequences of LRRs 11-14 from 
human (Uniprot code O60603), murine (Q9QUN7), cynomolgus monkey (Q95M53) and porcine 
(D3JEM3) TLR2 were aligned. Conserved residues identified as part of the TLR2/Fab interaction 
interface are highlighted in green. Residues involved in the TLR2 dimerization with TLR1 and TLR6 are 
highlighted in red. Alignment was performed with ClustalW version 2 (Larkin et al., 2007; Thompson et 
al., 1994). 
 
The epitope analysis confirms the interpretation that the conserved and exposed amino 
acids highlighted in Figure  IIIA-23 are likely to be involved in the TLR2/OPN-305 
interaction. For verification, different residues were chosen to perform single and 
multiple point mutations to analyze their influence on the antibody affinity using 
fluorescence-activated cell sorting (FACS) and immunoprecipitation experiments. 
These trials are currently in progress with our cooperation partner Opsona. 
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IIIA.4 Crystallization of the complex 
The TLR2/Fab complex used for crystallization was shown to be pure and stable in 
solution in the experiments described above. In addition, no aggregates could be seen on 
EM images, indicating the solution to be monodisperse. More than 1000 crystallization 
conditions were tested at different protein concentrations (5-20 mg/mL) and 
temperatures (4 °C, 16 °C and 20 °C). First protein crystals of TLR2/Fab (Figure 
 IIIA-24, A) were obtained after 3 weeks for a protein concentration of 20 mg/mL at 
16 °C by cross-seeding with InlC crystals from Listeria monocytogenes (provided by 
Lilia Polle, UWC, Cape Town, South Africa) under one distinct condition, comprising 
0.1 M MES buffer pH 6, 0.1 M MgCl2, and 8 % PEG6000. These needle clusters were 
then used for crystal optimization using microseeding so as to obtain single and bigger 
crystals suitable for diffraction experiments. Crystals could be reproduced, however all 
resulted in needle clusters (Figure  IIIA-24, B+C) or single, but very fragile and thin 
needles (Figure  IIIA-24, C+D). 
 
 
Figure  IIIA-24 Crystals of TLR2/Fab 
Different shapes of crystals from different stages of optimization are shown. (A) Initial needle clusters 
from cross-seeding. (B) Reproduction of needle clusters. (C) Sporadic single needle crystals within 
clusters. (D) Thin and long needles. (E) Crystals grown together. (F) Single crystal. 
 
One parameter that may lead to larger and better crystals involves increasing the protein 
solubility to reduce the rate of crystal growth speed. This may be achieved by adding 
higher salt concentrations and/or glycerol. In this case higher MgCl2 concentrations 
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proved successful in increasing the crystal size to up to 300 µm x 200 µm (250 mM 
MgCl2, Figure  IIIA-24, E). 
The best crystal of TLR2/Fab was obtained after 2 month by decreasing the protein 
concentration to 11 mg/mL and in presence of glycerol (0.1 M MES buffer pH 6, 0.12 
M MgCl2, 10% PEG6000, 3% glycerol, 16 °C) (Figure  IIIA-24, F). This single, large 
crystal (~500 µm x 200 µm x 200 µm) resulted in weak and smeared diffraction spots to 
~8 Å on a rotating anode generator (Rigaku MicroMax-007HF) and CCD detector 
(Rigaku Saturn944HG) (Figure  IIIA-25). 30 % glycerol was used as cryoprotectant. 
Indexing of the diffraction images using the HKL3000 package identified the most 
likely the Bravais lattice as C-centered orthorhombic. Unit cell dimensions are a = 
176 Å, b = 310 Å, and c = 97 Å. 
 
Figure  IIIA-25 Diffraction pattern of TLR2/Fab crystal 
Diffraction of TLR2/Fab (crystal see Figure  IIIA-24, F). The position of the direct beam is indicated by a 
green cross, the red circle marks the resolution shell of 8.0 Å. 
 
A complete dataset was collected, integrated and scaled using HKL3000 programmes 
Denzo and Scalepack. The weak and anisotropic diffraction pattern as well as the 
excessively high crystal mosaicity (>3°) resulted in poor scaling parameters and a mere 
Results 75 
3413 unique reflections for structure solution and refinement. The completeness of this 
dataset to 7.9 Å resolution is 98.9 %, the redundancy amounts to 2.6. The Rsym in the 
shell of highest resolution is 64 % (overall Rsym = 16 %). Matthews coefficient 
calculation resulted in Vm = 2.9 Å3/Da assuming two molecules per asymmetric unit 
with a solvent content of 57 %.  
Structure determination by molecular replacement was attempted using programs 
PHASER and MOLREP from the ccp4 software package. Search models included 
mTLR2 ECD with and without hagfish domain (crystal structure from Jin et al. 2007) 
and OPN-305 Fab domain with and without CDRs (structure modeling described in 
 IIB.10). No significant correlation for the models and the dataset were obtained. All 
MOLREP runs resulted in low “contrast values” (<1.5), a score for the probability of 
correct solutions calculated as a ratio of the top score to the mean score. 
Correspondingly MOLREP did not output a coordinate file. In PHASER, likewise no 
unique solution with meaningful parameters could be found. The highest Z-score for a 
solution after the fast rotation function was 4.2. A value of >5 is considered as a 
probable correct solution. The best Z-score after the fast translation function was 5.3 
(values >6 are considered as correct solutions). Moreover, packing check revealed 
numerous clashes. The fewest clashes found for a solution were 13. Solutions for which 
PDB files were output did not confirm the arrangement of TLR2 and Fab observed by 
EM. Electron density was only observable as a “random distribution”. 
Heterogeneous glycosylation of TLR2 can negatively affect the homogeneity of a 
protein solution adversely affecting protein crystal packing quality and hence diffraction 
quality. Therefore, in addition to the experiments with glycosylated TLR2 described 
above, TLR2 was also deglycosylated with PNGase F prior to complex formation and 
crystallization (see  IIIA.1.2). Alternatively, PNGase F was added directly to the 
crystallization experiment using 1 unit PNGase F per crystallization drop. This 
treatment did, however, not improve crystal quality, though further experiments are still 
ongoing. 
Other crystallization parameters that were explored but did not positively impact the 
crystal quality included incubation of crystallization plates at 4 °C, screening for new 
lead conditions using self-seeding, use of additives (Additive Screen, Hampton 
Research, California, USA) or purifying TLR2/Fab by anion-exchange  rather than size 
exclusion chromatography. 
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Although attempts at solving the crystal structure of TLR2/Fab were not successful, the 
crystals that were obtained constitute a promising starting point for further experiments 
in this direction. 
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IIIB Producing mouse/human Toll-like receptors 2 and 6 in 
insect cells using the baculovirus expression system 
The work described in this chapter was undertaken during the first 1½ years of this 
thesis at the HZI (Braunschweig, Germany). It was discontinued due to the publishing 
of the crystal structure of the TLR2/TLR6 complex (Kang et al., 2009). This event 
further coincided with the relocation of our research group to the University of the 
Western Cape, Cape Town, South Africa, where a lack of insect cell culture facilities 
and of corresponding experience prevented the continuation of this type of 
investigation. 
 
IIIB.1 Cloning 
A first step of the cloning procedure of TLR2 and TLR6 involved replacing the native 
secretion signal peptides by that of glycoprotein 67 (gp67) of Autographa californica 
nuclear polyhedrosis virus. The latter is known to lead to high levels of secretion and is 
therefore frequently used to boost the rate of secretion in the baculovirus system. The 
peptide is cleaved by the cell’s native signal peptidase as part of the secretion process. 
The central idea was to produce the TLR ECDs recombinantly as a fusion protein with a 
C-terminal His8-tag followed by an antibody “Fragment crystallizable” (Fc)-tag for 
rapid purification using Ni-NTA and protein A-sepharose affinity chromatography. The 
inclusion of a TEV protease cleavage site between the His6- and Fc-tags would allow 
the facile removal of the Fc-tag as part of the purification procedure (Figure  IIIB-1).  
 
Figure  IIIB-1 Scheme of the recombinant constructs of TLR2 and TLR6 expressed in Sf21 cells 
The native signal peptide was replaced by gp67. The TLR ECD is C-terminally linked to a His8- and an 
Fc-tag. A TEV protease cleavage site between the two tags allows for the removal of the Fc-tag during 
purification. 
 
The Fc-tag, a dimer of the C-terminal half of human antibody heavy chains, is 
recognized by Protein A of Staphylococcus aureus with a nanomolar dissociation 
constant, theoretically allowing for a highly efficient enrichment and purification of the 
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protein in a single step. This strategy of combining a gp67 signal with an Fc-tag in the 
TLR constructs was based on a similar approach by Jin et al. (2007). 
The produced recombinant proteins and their theoretical properties are listed in Table 
 IIIB-1. 
 
Table  IIIB-1 Properties of proteins 
Construct Length [aa] Molecular 
weight [kDa] 
Isoelectric 
point 
Glycosylation 
sites 
human TLR219-588-
His8-TEV-Fc 
822 92,9 6,05 4 + 1 
human TLR632-586-
His8-TEV-Fc 
807 92,1 6,44 9 + 1 
mouse TLR225-587-
His8-TEV-Fc 
815 91,9 6,10 3 + 1 
mouse TLR628-584-
His8-TEV-Fc 
809 91,8 6,53 10 + 1 
Fc 231 26 7,72 1 
human TLR219-588-
His8 
588 66,7 5,77 4 
human TLR632-586-
His8 
573 65,9 6,23 9 
mouse TLR225-587-
His8 
583 65,7 5,82 3 
mouse TLR628-584-
His8 
575 65,6 6,33 10 
 
The recombinant proteins have different numbers of N-linked glycosylation sites 
depending on the TLR type and the mammalian species plus an additional site in the Fc 
region (Table  IIIB-1). The molecular weight (MW) shown in this table is calculated 
from the amino acids ignoring the glycosylation. Insect cells glycosylate proteins 
posttranslationally. However the variability of the glycosylation and later processing 
(~1-3 kDa per glycosylation site) prevent the accurate prediction of the true MW. 
For simplicity, the four recombinant proteins human TLR219-588-His8-TEV-Fc, human 
TLR632-586-His8-TEV-Fc, mouse TLR225-587-His8-TEV-Fc and mouse TLR628-584-His8-
TEV-Fc will henceforth be denoted hTLR2-His-Fc, hTLR6-His-Fc, mTLR2-His-Fc and 
mTLR6-His-Fc. 
The cloning strategy to form the recombinant pFastBac1 (pFB) plasmids necessary for 
Bacmid-DNA generation involved four individual steps: i) PCR amplification of the Fc 
fragment from a donor plasmid using primers yielding a TEV-Fc DNA fragment 
flanked by appropriate restriction sites (Figure  IIIB-2, A), ii) cloning of TEV-Fc into the 
vector pFB (Figure  IIIB-2, B), iii) cloning of synthesized gp67-hTLR632-586-His8 
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fragment into pFB-TEV-Fc (Figure  IIIB-2, C and D), and iv) replacement of hTLR6 
ECD by mTLR2 ECD, mTLR6 ECD and hTLR2 ECD genomic DNA (Figure  IIIB-3). 
All products were verified by sequencing. Using the Tn7 sites of pFB the target DNA 
was then integrated into the Bacmid-DNA by site-specific transposition.  
 
 
Figure  IIIB-2 Cloning of pFB-gp67-hTL6-His-TEV-Fc 
Agarose gel electrophoresis was performed to analyze the individual cloning products. (A) PCR products 
after amplification of hFc from the plasmid pCMV-hFc-XP using primers yielding a TEV-hFc DNA 
fragment. (B) TEV-hFc fragment and pFB were cut with restriction enzymes and ligated to form pFB-
TEV-hFc. After cloning, a test restriction was performed to cut the insert. Samples bearing inserts with 
correct size are marked with an “x”. (C) The synthesized DNA fragment gp67-hTLR6-His8 (left gel) and 
pFB-TEV-hFc (right gel) were digested with the same restriction enzymes and analyzed on the agarose 
gel. (D) gp67-hTLR6-His8 was cloned into pFB-TEV-hFc. The success of the ligation was verified by 
cutting of the cloned insert and analysis of the DNA fragments on the agarose gel. Molecular weight 
marker: Smart Ladder (Eurogentec). 
 
 
Results 80 
 
Figure  IIIB-3 Cloning of hTLR2, mTLR6 and mTLR2 
pFB plasmids bearing hTLR2, mTLR6 and mTLR2 were cloned by replacing hTLR6 in pFB-gp67-hTL6-
His-TEV-Fc. (A) Enzymatic restriction of the plasmid yielding pFB-gp67-/-His8-TEV-hFc (1), PCR 
products of hTLR2 (2) and mTLR6 (3), purified and restricted PCR products of hTLR2 (4) and mTLR6 
(5), and test restriction of the final plasmids by cutting of hTLR2 (6) and mTLR6 (7). (B) PCR products 
of mTLR2 (1-4), and test restriction of the final plasmid by cutting of mTLR2 (5). Molecular weight 
marker: Smart Ladder (Eurogentec). 
 
For a detailed description of the cloning strategy, see Materials and Methods ( IIC.1).  
 
IIIB.2 Virus amplification 
After generating and isolating bacmid-DNAs encoding the four TLR gene constructs 
(denotation of the clones: mouseTLR2-K9-MP1, mouseTLR6-K14-MP1, humanTLR2-
K3-MP2, humanTLR6-K7-MP3), the DNA was transfected into Sf21 insect cells. The 
transfected cells were incubated in ExCell medium for the initial virus production. A 
plaque assay was performed after 48 h of incubation to determine the virus 
concentration in the medium (plaque forming units per milliliter, pfu/mL). Knowing the 
titer in solution the virus was amplified using a MOI (multiplicity of infection) of 0.1 – 
0.5, which is the ratio of viruses to cells during infection. In the case of mTLR2-His-Fc 
and mTLR6-His-Fc three circles of amplification and plaque assay were performed to 
obtain a final volume of 700 mL with a virus titer of 1.0 x 108 (mTLR2-His-Fc) and 0.7 
x 108 (mTLR6-His-Fc) pfu/mL respectively. For hTLR2-His-Fc and hTLR6-His-Fc the 
virus was amplified in a single step to a volume of 100 mL with a virus titer of 0.4 x 107 
(hTLR2-His-Fc) and 1.1 x 107 (hTLR6-His-Fc) pfu/mL respectively (Table  IIIB-2). An 
example of a plaque assay is shown in Figure  IIIB-4. During amplification, the shape, 
cell density and vitality of the virus infected cells, were monitored daily to control the 
infection efficiency. Cell rounding was observed due to the virus production within the 
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cells, leading to a swelling of the mean cell diameter to above 20 µm (Table  IIIB-2) and 
finally to the cell death. The viruses were harvested 4-5 days after infection, if the 
vitality of the cells was reduced to at least 60%. 
 
Table  IIIB-2 Virus amplification of the four TLR clones 
 Mean 
diameter 
Peak 
diameter 
Virus titer 
[pfu/mL] 
Final volume  
virus solution 
  
 after transfection 
mTLR2-His-Fc   3.9 x 105 4 mL 
mTLR6-His-Fc   1.6 x 106 4 mL 
hTLR2-His-Fc   1.5 x 10 7 4 mL 
hTLR6-His-Fc   1.1 x 10 7 4 mL 
 after 1st virus amplification 
mTLR2-His-Fc 20.9 µm 21.9 µm 0.5 x 10 7 15 mL 
mTLR6-His-Fc 20.4 µm 22.1 µm 1.5 x 10 7 15 mL 
hTLR2-His-Fc 21.1 µm 21.2 µm 0.4 x 10 7 100 mL 
hTLR6-His-Fc 21.1 µm 21.3 µm 1.1 x 10 7 100 mL 
 after 2nd virus amplification 
mTLR2-His-Fc 20.7 µm 20.6 µm 1.3 x 10 7 30 mL 
mTLR6-His-Fc 20.3 µm 20.6 µm 2.5 x 10 6 30 mL 
 after 3rd virus amplification 
mTLR2-His-Fc 22.1 µm 22.2 µm 1.0 x 108 700 mL 
mTLR6-His-Fc 22.1 µm 22.1 µm 0.7 x 108 700 mL 
 
 
 
Figure  IIIB-4 Plaque assay from amplified virus 
Assay of hTLR2-His-Fc and hTLR6-His-Fc after the 1st round of virus amplification and of mTLR2-His-
Fc and mTLR6-His-Fc after the 2nd round. Three virus dilutions (10-4, 10-5, 10-6) were analyzed. White 
plaques were counted to calculate the virus concentration. One plaque derives from a single virus 
infecting a single cell. Positive controls (PC, Toshi virus with known titer) and negative controls (NC, 
medium) were performed. 
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IIIB.3 Expression test 
The amplified virus was used in an expression test to establish its ability to induce 
expression and secretion of soluble protein in insect cells. 20 mL of cells using a MOI 
of 2 were used. Samples of the cell supernatant were taken 24 h, 48 h and 72 h after 
infection. Produced and secreted protein in the samples was identified by Western 
blotting using an anti-His6-tag antibody (Figure  IIIB-5). 
 
 
Figure  IIIB-5 Expression of TLR constructs in insect cells 
Western blot of mTLR2-His-Fc, mTLR6-His-Fc, hTLR2-His-Fc and hTLR6-His-Fc expressed in Sf21 
insect cells for 24 h, 48 h and 72 h. Produced protein was detected after 48 h and 72 h in the case of 
mTLR2-His-Fc, mTLR6-His-Fc and hTLR2-His-Fc, but not in the case of hTLR6-His-Fc. Molecular 
weight marker: “Precision Plus Protein All Blue Standard” (BioRad). 
 
The Western blot indicates that mTLR2-His-Fc and hTLR2-His-Fc had successful been 
produced after 48 h and 72 h incubation. Trace amounts of mTLR6-His-Fc were 
produced after 72 h, while hTLR6-His-Fc does not appear to be produced. Depending 
on the number of glycosylation sites and degree of glycosylation, the actual molecular 
weight of the produced proteins is about 10 kDa (mTLR2-His-Fc) to 20 kDa (mTLR6-
His-Fc and hTLR2-His-Fc) higher than the theoretical weight (~92 kDa, see Table 
 IIIB-1) calculated from the amino acid composition. 
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The secretion rate of mTLR2-His-Fc was compared to that of soluble and insoluble 
intracellular protein (Figure  IIIB-6). 
 
Figure  IIIB-6 Secretion rate of expressed mTLR2-His-Fc 
Protein samples were extracted with Cytobuster reagent (Novagen) from 4 x 106 cells separated into 
(Secr), intracellular soluble (S) and intracellular insoluble (IS) fractions. Molecular weight marker (M): 
“PageRuler Unstained Ladder” (Fermentas). 
 
A strong band in the insoluble fraction indicates that the largest fraction of mTLR2-His-
Fc ends up in intracellular inclusion bodies. A smaller fraction is successfully secreted 
as seen in a band at about 100 kDa in the secretion fraction matching the band of 
mTLR2-His-Fc observed in the Western blot. 
 
IIIB.4 Protein purification 
Protein purification was performed to analyze if the properties of the designed 
recombinant proteins with Fc-tag and TEV protease cleavage site (Figure  IIIB-1) can be 
optimally used. 
A sample of each produced protein was purified to establish whether the His6- and Fc-
tags as well as the TEV protease cleavage site (Figure  IIIB-1) are functional. The first 
step involved Protein A affinity chromatography (AC): Each protein fraction was mixed 
with Protein A sepharose matrix to allow protein coupling. The matrix was then washed 
with buffer to remove any impurities. The protein composition of matrix beads and 
wash fractions was analyzed by SDS-PAGE (Figure  IIIB-7). 
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Figure  IIIB-7 Purification of TLR-His-Fc by Protein A affinity chromatography 
For each TLR species two wash fractions (W1 + W2) and a matrix beads fraction (B) were collected and 
applied on the gel. Molecular weight marker (M): “PageRuler Unstained Ladder” (Fermentas). 
 
As previously observed in the Western blot, mTLR2-His-Fc and hTLR2-His-Fc were 
most strongly produced, mTLR6-His-Fc was produced to a significantly lower level, 
whereas hTLR6-His-Fc was not expressed at all. The band corresponding to mTLR6-
His-Fc (115 kDa) ran slightly above that of mTLR2-His-Fc and hTLR2-His-Fc 
(105 kDa) due to the higher degree of glycosylation. 
Overall the fusion proteins were enriched and separated from any other proteins very 
efficiently by Protein A AC. Only weak bands corresponding to impurities can be 
observed at ~30 kDa in the lanes containing the bead samples (Figure  IIIB-7, lanes B). 
In a next step, the attempt was made to elute the target proteins from the column by 
TEV protease cleavage, after which the Fc-tag would remain bound to the column and 
TLR-His could be collected in the flow through. 
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Figure  IIIB-8 TEV protease cleavage of TLR-His-Fc 
Flow through and matrix beads samples of mTLR2-His-Fc (m2), mTLR6-His-Fc (m6), hTLR2-His-Fc 
(h2) and hTLR6-His-Fc (h6) after TEV protease cleavage were analyzed by SDS-PAGE. TEV protease 
(TEV) was run as control. Molecular weight marker (M): “PageRuler Unstained Ladder” (Fermentas). 
 
The beads were incubated with TEV protease over night at 4 °C. The soluble fraction 
was then eluted and the beads washed with buffer. The SDS gel (Figure  IIIB-8) reveals 
bands at 60 kDa and between 70 kDa and 85 kDa for all protein samples. By 
comparison with a TEV protease control these were identified as impurities in this 
preparation. The common bands therefore need to be ignored in analyzing the protein 
samples.  
The TEV protease should have cleaved each TLR-His8-Fcs into two protein fragments: 
TLR-His8 of about 70 kDa (65 kDa + glycosylation) in the flow through and Fc of about 
30 kDa (26 kDa + glycosylation) bound to the matrix (see properties in Table  IIIB-1). 
However, no bands other than the TEV protease and its impurities are visible in the 
eluted fractions. Instead, a weak band at 70 kDa is apparent for the bead sample m2 
matching the expected size of cleaved mTLR2-His. The same lane reveals several 
additional bands above the TEV protease at about 32-35 kDa, which may represent the 
Fc-tag.  
This result suggests that partial cleavage of mTLR2-His-Fc appears to have taken place 
but that the larger fraction of the protein was uncleaved and remained bound to the 
matrix. Liberated mTLR2-His possibly aggregated or bound unspecifically to the beads, 
preventing it from elute from the column. The same may be true for hTLR2-His-Fc, but 
the protein concentration was too low to visualize the protein on the gel. Longer 
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incubation of the protein-coupled matrix with TEV protease at room temperature did 
not lead to an increase in elution of the protein. 
To confirm the identity of the bands between 30-35 kDa in Figure  IIIB-8 as the Fc-tag, 
a Western blot was run on TEV protease cleaved samples using an anti-Fc antibody to 
identify the Fc fragment. 
 
 
Figure  IIIB-9 Western blot of TLR-His-Fc after TEV protease cleavage 
mTLR2-His-Fc (m2), mTLR6-His-Fc (m6), hTLR2-His-Fc (h2) and hTLR6-His-Fc (h6) were incubated 
with TEV protease. After cleavage, flow through and matrix beads samples were analyzed on a Western 
blot by immunostaining with an anti-Fc antibody. Molecular weight marker (M): “PageRuler Prestained 
Ladder” (Fermentas). 
 
As expected, no bands were identified in the flow through fractions by immunostaining 
with an anti-Fc antibody (Figure  IIIB-9). The proteins mTLR2-His-Fc and hTLR2-His-
Fc were stained in the beads fractions. Furthermore, several bands can be observed 
between 25 kDa and 35 kDa - similar to the SDS-PAGE in Figure  IIIB-8 - even in the 
lanes for mTLR6 and hTLR6 where no uncleaved proteins could be detected. The 
identification of the Fc fragment confirms that all recombinant proteins were partially 
cleaved. The varying sizes of Fc can be explained by heterogeneous glycosylation of the 
protein. 
 
Because of the high affinity of Protein A for Fc-tagged proteins, the only method of 
eluting the uncleaved fusion-protein would be to change the pH to below pH 4. This 
would risk precipitating the protein. Correspondingly, elution of fusion proteins with 
acidic buffer led to their irreversible denaturation. 
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IIIB.5 DNA constructs: New strategies 
As the last experimental part in this project, two modifications of the previous DNA 
constructs were designed to improve secretion and purification of the TLR variants. 
The first approach involved inserting a stop codon directly downstream of the His8-tag 
by quick change mutagenesis to remove the uncleavable Fc-tag. The aim was to test 
whether the Fc-tag itself negatively affected the secretion of the protein. Were this so, 
the four proteins could then have been produced and purified without the additional 
purification tag. 
 
Figure  IIIB-10 Agarose gel of TLR plasmids after stop codon insertion 
NheI/NotI restriction of TLR-His-Fc plasmid-DNA after mutagenesis. From each TLR species, the DNA 
from three colonies (1-3) was analyzed. Successful mutagenesis would have removed a NheI site and 
resulting in a single, linearized band. Unchanged clones would show an additional band at 700 bp 
resulting from NheI/NotI. At least one positive clone could be isolated from each TLR construct. 
Molecular weight marker: Smart Ladder (Eurogentec). 
 
A stop codon was inserted within a NheI restriction site, downstream of the His8-tag. 
Successful mutagenesis would therefore remove the NheI site. For verification, the 
isolated DNA was digested with NheI and NotI (Figure  IIIB-10). Positive clones were 
identified as single bands of linearized DNA on the agarose gel, whereas negative 
clones resulted in an additional band between 600 and 800 bp. One positive clone was 
chosen from each TLR variant and was sent for sequencing. 
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In a second approach, a 15 base pair spacer was to be inserted between the TEV 
protease cleavage site and the Fc-tag by quick change mutagenesis to improve steric 
access of TEV protease to the encoded cleavage site increasing the efficiency of the 
protease (Figure  IIIB-11). 
 
TLR Spacer Forward Primer 
     15 bases N-Term         Loop      15 bases C-Term 
CTTTATTTTCAGGGC GGTGCGGGCGGTGAG CCCAAATCTTGTGAC 
   TEV protease site       Fc-tag 
 
TLR Spacer Reverse Primer (reverse complement to forward primer) 
     15 bases N-Term         Loop       15 bases C-Term 
GTCACAAGATTTGGG CTCACCGCCCGCACC GCCCTGAAAATAAAG 
  Fc-tag             TEV protease site 
Figure  IIIB-11 Loop insertion between TEV site and Fc tag 
The base sequence GGTGCGGGCGGTGAG coding for the amino acids GlyAlaGlyGlyGlu was inserted 
as a linker between the TEV protease cleavage site and the Fc-tag to improve steric access to the cleavage 
site by TEV protease. 
 
 
All TLR constructs were successfully modified according to both mutagenic strategies, 
verified by sequencing, and hence provide a potential starting point for new bacmid-
DNA generation, insect cell protein expression and purification trials. These 
experiments were not performed as part of this thesis due to the reasons outlined above. 
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IV Discussion 
IVA Negative stain EM of TLR2/OPN-305 
Negative stain EM is a common technique to image macromolecules. The biomolecules 
are embedded in a dried film of heavy-metal salt such as uranyl acetate to fix the 
specimen on the grid and to surround the specimen with a strong electron scatterer. It 
leads to high contrast images as mainly the surrounded stain but only little the specimen 
is deflecting the incoming electrons. Inherently, the final resolution is limited by the 
grain size to ~20 Å (Wang and Sigworth, 2006). Cryo-EM is an alternative technique, in 
which the protein specimen is rapidly cooled to below -160 °C without any stain. It 
allows for molecular resolution in the range of 10 Å and higher. However, the signal-to-
noise ratio and the contrast of cryo-images are lower than for negative stain EM (Wang 
and Sigworth, 2006). This technique is therefore more suitable for large 
macromolecules above 500 kDa which inherently result in a stronger signal. Examples 
in this size range include membrane channels (Ludtke et al., 2005), ribosome subunits 
(Stark, 2002) or chaperonins (Falke et al., 2005). Obtaining structural information for 
the 117 kDa complex of mTLR2/OPN-305 by cryo-EM was attempted as part of this 
project. However, these were not been successful as no molecules were observable 
under the microscope. The resolution for the complex of mTLR2/OPN-305 is close to 
the theoretical limit for negative stain experiments and is thus comparable (Kim et al., 
2004) or even better (Pruitt et al., 2010) than other structures solved by negative EM. 
 
IVA.1 The EM docking: models and orientations 
OPN-305 is a humanized version of the parent OPN-301 murine IgG1 antibody. This 
was done to reduce its immunogenicity in humans as compared to murine antibodies. 
The humanized antibody retains the efficiency of the original murine version in in vitro 
cell based bioassays (OPN-305 patent, International Patent Number WO/2011/003925, 
Opsona Therapeutics). However, no OPN-305 crystal structure is currently available for 
EM density docking. As the antibody was created by grafting CDR loops onto a human 
IgG4 framework, we similarly used the crystal structure of the Fab fragment of IgG4 
antibody b12 (PDB code 2NY7), which shares a high sequence identity with OPN-305 
of 84 % (heavy chain) and 87 % (light chain), respectively, when excluding the CDRs. 
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Sequence differences exclusively occur in the variable domains of light and heavy 
chain. To optimize the antibody model, the CDR loops of b12 were replaced with those 
of OPN-305, modeled using the structure modeling server Swiss-Model. Overall, 
Qmean4 scores of 0.818 and 0.685 for heavy chain and light chain, respectively, suggest 
a high reliability of the model (see Results, Figure  IIIA-16). Z-scores of 0.14 for the 
heavy chain and -1.19 for the light chain are close to zero and indicate a high likelihood 
that the model is of comparable quality to experimental structures. Based on the Anolea 
and Qmean scores for the individual amino acid residues, the weakest reliability was 
calculated for the CDR regions. For more details about Swiss-Model model evaluation, 
see Material and Methods  IIB.10. 
Although an increasing number of crystal structures of antibody Fab domains are being 
solved, predicting the conformation of CDRs still remains a difficult task, as the 
variable loops demonstrate a significant range of lengths, sequences and conformations 
(Shirai et al., 1999). Analysis of more than 300 crystal structures of antibody variable 
domains, 80 conformational clusters were identified and CDRs were grouped by their 
length combinations (North et al., 2010). CDRs for all crystal structures except H3 fall 
within a favoured length distribution. Thus 45 % of light chain CDR 1 (L1) comprises 
11 residues – summarized as “L1: 45%/11”. Figures for the remaining CDRs are L2: 
98%/8; L3: 85%/9; H1: 93%/13; H2: 67%/10. Four of six CDRs in OPN-305 Fab (L2, 
L3, H1 and H2) fall within these dominant groups of CDR lengths. L1 with a length of 
15 residues belongs to a minor cluster comprising 4% of structures, whereas H3 with 11 
residues shares this with 8% of structures. Prediction of L2, L3, H1 and H2 
conformations would therefore presumably be more accurate due to the availability of 
more reference structures for homology modeling. In accordance, Swiss-Model Anolea 
and Qmean scores indicate a lower model quality especially for H3 (see Results, Figure 
 IIIA-16). The Swiss-Model scores for L1, L2, L3, H1, and H2 show comparable values. 
While the length and sequence of the CDRs for OPN-305 Fab are known and are 
correctly reflected in our generated structural model, the determination of the true CDR 
conformations would need to be determined by high resolution techniques such as X-
ray crystallography. 
As Fab fragments have an approximate 2-fold rotational symmetry around the longest 
axis of the domain, the OPN-305 Fab structural model has been initially modeled in two 
possible orientations (denoted Fab#1 and Fab#2) into the EM derived molecular 
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surface. By comparison of the two orientations, it was possible to constitute Fab#2 
beeing the more probable orientation. Fab#2 reveals a better agreement of structural 
model and EM molecular surface by showing fewer clashes between model and EM 
surface (see Results, Figure  IIIA-18). 
 
Crystal structures of mTLR2 are available for lipopeptide-bound monomers (Jin et al., 
2007) and for the complex with lipopeptides and mTLR6 (Kang et al., 2009). To 
optimally explain the EM-derived molecular surface, we chose the crystal structure of 
monomeric mTLR2 (PDB code 2Z81) as this provides the most accurate structural 
information at a resolution of 1.8 Å. All currently available TLR2 structures constitute 
hybrid molecules in which LRR modules of the hagfish Variable Lymphocyte Receptor 
(VLRs) replace the C-terminal amino acids 507-587 of the TLR2 ECD including 
capping domain (Jin and Lee, 2008a). We have chosen to make use of these hybrid 
TLR2 ECD-VLR structures in lieu of TLR2 ECD in interpreting the EM results and to 
analyze the interaction between OPN-305 and TLR2. This was done because i) VLRs 
adopt standard LRR conformations (Jin and Lee, 2008a), ii) the mTLR2-VLR chimera 
is similar in length to native mTLR2 and iii) the VLR domain is not itself in contact 
with the antibody. 
Similar to the Fab fragment, the almost planar shape of TLR-ECD results in an 
approximate 2-fold rotational symmetry allowing mTLR2 to be placed into the EM 
molecular surface in two orientations (denoted as TLR#1 and TLR#2). In TLR#1, the 
surface area involved in dimerization with TLR1 and TLR6 faces the OPN-305 Fab 
fragment, whereas the dimerization site would face away from the Fab in TLR#2. Major 
clashes with the EM molecular surface could be observed for TLR#2 (see Results, 
Figure  IIIA-19). Coincidentally, as outlined above, the TLR2/TLR1 or 6 dimerization 
surface of TLR2 faces the variable domain of OPN-305 in TLR#1, providing and 
immediate structural explanation for the neutralizing effect of this antibody in that this 
site would be completely blocked by the antibody, preventing dimerization of TLR2 
with either TLR1 or TLR6 and hence downstream signaling. Based on these 
observations TLR#1 was identified as the correct orientation. 
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IVA.2 The antibody epitope on TLR2 
Following the determination of the correct orientations for both Fab and TLR2 within 
the EM-derived molecular surface, the inhibition of TLR2 by OPN-305 can be clearly 
described in structural terms as the physical blocking of the dimerization site on the 
TLR2 surface by OPN-305. Correspondingly, OPN-305 binding to TLR2 sterically 
prevents TLR1 or TLR6 from accessing the dimerization interface and hence from 
forming heterodimers with TLR2. OPN-305 therefore specifically inhibits the TLR2-
dependent pro-inflammatory response. This interpretation directly confirms the 
observation that OPN-305 inhibits Pam3CSK4-induced production of IFN-γ, IL-1β, IL-
6, TNF-α and IL-8 in mononuclear cells in peripheral blood and synovial fluid and also 
inhibits spontaneous cytokine production in rheumatoid arthritis synovial tissue explant 
cultures ex vivo (Ultaigh et al., 2011). The inhibition is dose dependant, and in a sepsis 
model in mice cytokine production induced by Pam3CSK4 could be completely ablated 
by systemic pretreatment with 2 mg/kg OPN-301 (Farrar et al., 2011). The same authors 
used a concentration of 10 mg/mL for in vivo, post-renal transplantation in mice to 
analyze the effect of OPN-301 on postischemic renal failure and observed a 
significantly improved renal function. The half-life of the antibody is 8-9 days and 
remains functional over a period of 14 days (Farrar et al., 2011). This observation is 
consistent with our laboratory experience of the antibody remaining structurally intact 
over weeks. For the prevention of I/R injury after organ transplants or myocardial 
infarction the pretreatment with antibodies with a long half-life is beneficial to stabilize 
the treated organ over a long time span by requirement fewer drug administrations 
(Arslan et al., 2010b). In animal and in vitro experiments no adverse effects have been 
noted for antibody blocked TLR2. OPN-305 is currently used in a healthy volunteer 
study to calculate the dosing for the phase II efficacy study (oral conservation with 
William McCormack, Opsona Therapeutics). 
Successful purification of the TLR2/OPN-305 Fab complex by size exclusion 
chromatography and the stability of the complex during native PAGE suggest a high 
binding affinity with a dissociation constant (KD) of 100 nM or below. The existence of 
a strong interaction is further supported by the observation that OPN-305 recognizes a 
discontinuous epitope involving surface-exposed residues from several LRRs. 
Experimental determination of the binding affinity by SPR spectroscopy yielded a KD = 
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11.9 nM for OPN-305 with mTLR2 and KD = 28.9 nM with hTLR2 (OPN-305 patent, 
International Patent Number WO/2011/003925, Opsona Therapeutics).  
 
 
Figure  IVA-1 Blocking of the ligand binding site by OPN-305 
Molecular surface of the ligand binding site (orange) of TLR2 (mint green) with and without OPN-305. 
(A) Top view of the ligand binding site with bound diacylated lipopeptide Pam2C (pink). (B) As (A) but 
including the antibody Fab. The latter blocks the entire ligand binding site of TLR2. (C) The two TLR2 
ligands diacylated lipopeptide Pam2C (pink) and triacylated Pam3CSK4 (green) are overlaid (direction of 
view indicated by a red arrow in A). (D) Equivalent view as C) but showing OPN-305 in molecular 
surface representation. The nitrogen-bound lipid chain of Pam3CSK4 as well as residues of the peptide 
clash with the antibody. 
 
IVA.2.1 Does OPN-305 blocks ligand binding? 
As demonstrated above, the presence of lipopeptide is not a prerequisite for TLR2/Fab 
complex formation. Correspondingly, TLR2 preincubated with OPN-301 does not bind 
to Pam3CSK4 immobilized on a chip surface during SPR analyses (Meng et al. 2004). 
Proposedly, masking of the ligand-binding pocket of TLR2 led to its inactivation. The 
entrance to the lipopeptide binding pocket in TLR2 is located between LRRs 11 and 12 
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(Jin et al., 2007) central to both the TLR/TLR dimerization surface and the antibody 
epitope (Figure  IVA-1, A). The inhibition observed by SPR spectroscopy was thus 
presumably due both to steric blocking of the Pam3CSK4 binding site as well as the 
physical size of the antibody preventing access to the TLR2 surface or the chip-bound 
ligand. Thus, while the inhibition of TLR dimerization clearly dominates the 
mechanism of antibody-induced TLR2 inactivation this does not resolve the question of 
overlapping binding sites for antibody and lipopeptide on TLR2. Hence, does binding of 
the ligand prevent, suppress or increase antibody binding? Alternatively, is the antibody 
able to displace the ligand or bind to TLR2 both in the presence and absence of the 
ligand? If so, are lipopeptides still able to diffuse in and out while the antibody is 
bound? In the case of competitive inhibition of antibody binding by the ligand, the 
concentration of antibody required for complete TLR2 neutralization would be 
significantly higher than in the case of antibody binding being independent of 
lipopeptide binding. 
 
Figure  IVA-2 Ligand access to the ligand binding pocket after antibody/TLR2 complex formation 
Lateral view of the ligand binding pocket. While the antibody covers most of the binding pocket, it 
nevertheless provides lateral access to the binding pocket potentially allowing ligand to diffuse in or out 
of the binding site. The conserved elements of lipopeptides including the acyl chains and the cysteine 
residue are not influenced by antibody binding. 
 
The two ester-bound acyl chains of lipopeptides fill a large pocket in TLR2 lined with 
hydrophobic residues from LRR modules 9-12. The third amide-bound acyl chain of 
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triacylated lipopeptides as well as the peptide moiety are not accommodated in this 
pocket but are involved in mediating TLR dimerization (Jin et al., 2007) (Figure  IVA-1, 
A). In the TLR2/Fab complex the antibody variable domain binds the surface of 
LRR11-14 and covers major parts of the ligand binding pocket (Figure  IVA-1, B). This 
would result in conflicts between the amide-bound acyl chain of triacylated lipopeptides 
such as Pam3CSK4 and the antibody surface (compare Figure  IVA-1, C+D). Therefore, 
binding of the antibody and triacylated lipopeptides are mutually exclusive and partly 
compete for the same binding site. In addition, the peptide group of Pam3CSK4 spatially 
overlaps with the antibody (Figure  IVA-1, D). Diacylated lipopeptides lacking the 
amide-bound lipid chain could potentially bind to TLR2 independently of the antibody 
binding, provided the peptide moiety is fairly short. In fact, the ligand binding pocket 
still appears accessible even after antibody binding potentially allowing small 
diacylated lipopeptides to diffuse in and out (Figure  IVA-2). A more highly resolved 
crystal structure could provide more detailed information on the size of narrowed 
binding pocket entrance. The lipopeptides Pam2CSK4 and Pam3CSK4 are, however, 
small synthetic molecules, significantly shorter than physiological lipopeptides that 
normally have longer peptides (see Figure  IB-1). In this case the antibody would 
directly compete with most natural lipopeptides. 
OPN-305 thus prevents TLR/TLR dimerization and obstructs the ligand binding site 
preventing lipopeptide-dependent cytokine release. In addition, the antibody also 
inhibits PGN-, LTA-, and DAMPs-dependent immune responses (Farrar et al., 2011; 
Meng et al., 2004). To date, their active sites have not been identified and a possible 
competitive inhibition of antibody binding by these ligands remains to be determined. 
 
IVA.2.2 The protein-protein interaction surface 
Our EM-based docking experiments clearly identify the surface loops of TLR2 LRR11-
14 as the discontinuous epitope recognized by the OPN-305 Fab fragment. An 
extended, flexible loop of LRR10 in mTLR2 (Figure  IVA-3) may additionally be 
involved but this is not certain from the current structural model. Its potential 
interaction partner is CDR-L1 of OPN-305, the conformation of which is also difficult 
to predict due to it having the rare length of 15 residues (see  IVA.1). In the TLR2 dimer 
structures LRR10 adopts a more compact fold than in the TLR2 monomer implying that 
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TLR1 or TLR6 binding induces the structural change (Figure  IVA-3, green and red 
structures, Jin et al. 2007). A compact structure as in the TLR dimers would move it 
away from CDR-L1. However, favorable interactions with CDR-L1 could, of course, 
result in a different interaction altogether. The degree of interaction therefore remains to 
be determined.  
Like LRR10, LRR11 also undergoes a conformational change after TLR dimerization 
moving it towards the ligand and allowing it to form multiple hydrogen bonds with it 
(Kang et al., 2009). As the EM analysis was undertaken without ligand, LRR11 would 
presumably adopt a conformation as seen in the monomeric mTLR2 (PDB code 2Z81), 
used as the model structure (Figure  IVA-3, green). The exact conformation is not 
critical for the current evaluation as it would remain in the centre of the epitope making 
its residues accessible by OPN-305. 
 
 
Figure  IVA-3 Structural changes in LRR10 and LRR11 induced by TLR dimerization 
Overlay of mTLR2 monomer (green, PDB code 2Z81) with mTLR2 from mTLR2/mTLR6 dimer (red, 
PDB code 3A79). In the crystal structure of TLR2/TLR6 the LRR10 of TLR2 adopts a compact 
conformation in contrast to the extended loop conformation in the crystal structure of the TLR2 
monomer. Only in the extended conformation LRR10 would be in contact with CDR-L1. Also note the 
dimerization-induced conformational changes in LRR11. 
 
Examining the location of the CDRs of OPN-305 relative to the surface of the LRRs, all 
six can be inferred to be involved in the protein-protein interaction (Figure  IVA-4, A). 
Several CDRs are positioned to interact with more than one LRR (Figure  IVA-4, B).  
 
Discussion 97 
 
Figure  IVA-4 TLR2/OPN-305 interactions 
All six CDRs of OPN-305 appear to be involved in recognizing TLR2. (A) Modeled conformation of 
CDRs (heavy chain CDRs: H1, H2, H3; light chain CDRs: L1, L2, L3) relative to the surface of the TLR2 
LRRs (LRR11-14, orange). Residues on the surface of TLR2 and potentially in contact with the antibody 
are highlighted in grey. (B) Schematic depiction of CDR/LRR interactions. The line colours correspond 
to the colour scheme of the CDRs in A. For a detailed description see the text below. 
 
By flanking the concave side of LRRs 12, 13 and 14, CDR-H1 would presumably 
interact with all three, whereas CDR-L2 aligns with the convex side of LRR12 and 
LRR13. CDR-H3 is situated almost in the centre of the ligand binding site between 
LRR11 and LRR12. CDR-L1, CDR-L3 and CDR-H3 face towards LRR11. In total, the 
extended LRR11 is surrounded by four CDRs (CDR-L1, CDR-L3, CDR-H2 and CDR-
H3), making this loop the major contributor within the described interaction. This 
underlines the preferred orientation of TLR2 within the EM surface of also being highly 
physiological reasonable for antibody interaction. The second, but unlikely orientation 
of TLR2 would strongly decrease the protein-protein interaction surface area and the 
number of CDR/LRR interactions (Figure  IVA-5). 
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Figure  IVA-5 LRR11 is a major contributor for CDR/LRR interactions 
(A) LRR11 is important for a strong protein-protein interaction as it is surrounded by several CDRs of 
OPN-305. (B) Modeling the unlikely orientation of TLR2 into the EM surface results in no comparable 
extended LRR at the position of LRR11 as seen in (A), which would strongly decrease the binding 
affinity and would leave several CDRs unbound. The more likely TLR2 orientation #1 as identified in 
Figure  IIIA-19 is thus highly physiological reasonable. 
 
Details of the interactions between OPN-305 CDRs and TLR surface residues can at 
present not be identified due to both the ambiguity of the modeled CDR region and the 
resolution inherent to the method. Nevertheless, potentially interacting residues in 
LRR11-14 have been identified based on the premise that the side chains should be 
directed outward and they should be conserved in the mammalian TLRs which OPN-
305 is known to antagonize. Of ten amino acids on the surface of LRR11-14 fulfilling 
the criteria outlined above for involvement in the interaction, eight are conserved in 
murine, human, apish (aTLR2) and porcine TLR2 (pTLR2) (see Figure  IIIA-22, Figure 
 IIIA-23). Compared to mTLR2, differences include an arginine at position 321 in 
hTLR2 instead of glutamine, and a phenylalanine at position 323 in porcine TLR2 
instead of tyrosine. SPR experiments previously indicated that OPN-305 has a slightly 
higher affinity to mTLR2 than to hTLR2 (mTLR2 KD = 11.9 nM, and hTLR2 KD = 28.9 
nM) (OPN-305 patent, International Patent Number WO/2011/003925, Opsona 
Therapeutics). This may be explained by the fact that the humanized antibody OPN-305 
is based on the murine anti-TLR2 antibody T2.5 (OPN-301), which was initially 
selected from mTLR2 immunized mice. The CDRs of OPN-305 are therefore optimized 
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for the recognition of mTLR2 surface residues. The exchange of glutamine 321 in 
mTLR2 to arginine 321 in hTLR2 could lead to the observed decrease in the binding 
affinity. 
 
IVA.2.3 Cross-reactivity of OPN-305 
The cross-reactivity of OPN-305 in a range of mammals is due to the conserved nature 
of the TLR dimerization interface indicating the specific interaction of TLR2 with 
TLR1 and TLR6 to predate the divergence of the mammalian lineages. The sequence 
identity of LRR11-14 between mTLR2 and hTL2 is 83 % compared to 63 % for the 
remainder of the ECD. Similar degrees of conservation can be observed between 
mTLR2/aTLR2 and mTLR2/pTLR2 (Table  IVA-1). As this region is critical for ligand 
binding and heterodimerization of TLR2 and hence for the protein functionality, amino 
acids within this area intolerant to spontaneous mutations. Mutations would 
immediately impact the TLR-mediated immune response and increase the risk of 
disease, making TLR2 an excellent antagonistic drug target (Hennessy et al., 2010). 
 
Table  IVA-1 Sequence identities 
 mTLR2/ 
hTLR2 
mTLR2/ 
aTLR2 
mTLR2/ 
pTLR2 
LRR11-LRR14 83 % 81 % 75 % 
ECD (w/o LRR11-
LRR14) 
63 % 63 % 61 % 
ECD  67 % 66 % 64 % 
 
Although cross-reactivity of OPN-305 with TLR2 from mammals other than human, 
mouse, cynomolgus monkey and pig have not been shown experimentally, it is likely 
that this antibody would also neutralize TLR2 from other species – the proviso being 
that the residues in the TLR2 epitope that are involved in the recognition are conserved. 
The amino acid sequences for TLR2 LRR11-14 from a range of animals have therefore 
been aligned to identify other potential targets for OPN-305 (Figure  IVA-6). In addition 
to the four mammals named above, TLR2 sequences came from chimpanzee, dog, 
cattle, goat, sheep, horse and Chinese hamster.  
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Figure  IVA-6 Multi-sequence alignment of the TLR2 epitope 
Murine, human, cynomolgus monkey and porcine TLR2 are known to be silenced by OPN-305. Their 
amino acid sequences were aligned with representatives of four additional mammalian families. 
Conserved residues in the proposed epitope of OPN-305 on TLR2 are highlighted in green. Alignment 
was performed with ClustalW version 2 (Larkin et al., 2007; Thompson et al., 1994). 
 
The amino acid sequence alignment reveals that despite individual mutations in the 
recognition site residues, all species share at least 7 of 10 residues of the mTLR2 
epitope. Proline 320 (mTLR2 numbering), lysine 347, phenylalanine 349, leucine 371 
and glutamate 375 are all perfectly conserved in all species. Histidine 318 is only 
replaced by arginine in equine TLR2. Even-toed ungulates (cattle, goat and sheep) have 
the lowest consensus, sharing only 7 of 10 critical residues with mTLR2. The sequence 
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of the hominid chimpanzee is identical to that of hTLR2, which coincidentally is also 
identical to that of canine TLR2.   
The sequence alignment implies that OPN-305 will presumably antagonize all studied 
TLR2s. The affinity may, however, be lower in some compared to mTLR2 due to fewer 
conserved interactions. The lowest affinity may be expected for cattle, goat and sheep. 
 
IVA.3 Crystallization of TLR2/OPN-305 
Although the TLR2/OPN-305 crystal structure could not be solved in this work, some 
major obstacles such as the purification of the corresponding molecules and the 
production of diffracting crystals up to a resolution of 8 Å were achieved. This chapter 
discusses the results in this work and how the strategies could be modified in future 
efforts to solve the crystal structure of TLR2/OPN-305. 
 
IVA.3.1 Optimization of protein purification 
A pure and monodisperse protein solution is crucial for the generation of high quality 
crystals. EM images reveal no aggregation of TLR2 and TLR2/OPN-305 (see Figure 
 IIIA-12) indicating that the purified proteins is essentially monodisperse and the 
interaction is stable. Correspondingly, the complex gives rise to a homogenous peak 
during AEC (see Figure  IIIA-11). By contrast, two Fab variants with a mass difference 
of 436 Da were identified by MS. These could not be separated completely (see Figure 
 IIIA-7). The size difference between the variants implies the loss of the amino acids 
Ser-Lys-Tyr-Gly at the C-terminus of the Fab heavy chain and is presumably the result 
of unspecific papain cleavage (see Figure  IIIA-8). Due to the similar size, shape and 
charge distribution, the complete separation of the two molecular species by liquid 
chromatography such as SEC (see Figure  IIIA-6) and cation exchange chromatography 
(data not shown) was not successful. Inhomogeneous papain cleavage has previously 
been observed (Bennett et al., 1997) and is due to the enzyme being a nonspecific 
sulfhydryl protease that cleaves most peptide bonds, though the rates of hydrolysis may 
differ by several orders of magnitude (Bennett et al., 1997). Antibodies are 
preferentially cleaved in the accessible hinge region (see Figure  IIIA-5) and papain has 
thus traditionally been used to generate Fab fragments. The broad substrate specificity 
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of papain can, however, lead to heterogeneous cleavage of the hinge region requiring 
some experimentation to identify the optimal digestion conditions for a particular 
substrate (Adamczyk et al., 2000). For monoclonal antibodies digestion parameters may 
vary considerably for different types and subclasses (Milenic et al., 1989). As a thiol 
protease, papain needs to be activated by a reducing agent (usually cysteine) prior to 
digestion. Much effort went into identifying conditions under which adequate amounts 
of high quality Fab fragments could be generated. For this purpose both enzyme and 
antibody concentrations were varied, as were the buffer constituents, the cysteine 
concentration and the incubation time. However, the secondary cleavage implies that 
the parameter will need to be further optimized. Possibly a longer incubation time or 
increase of enzyme concentration could potentially allow the secondary digestion to 
continue to completion producing a homogeneous sample of the shorter variant. 
A fundamentally different approach would be the recombinant production of a so called 
single-chain variable fragment (scFv) of OPN-305. A scFv is a fusion protein of the 
variable regions of heavy and light chain, connected by a short linker (Holliger and 
Hudson, 2005). The protein retains the specificity and affinity for its antigen and can be 
produced in bacteria (E. coli) as a homogenous protein, without the need of papain 
cleavage. 
 
mTLR2 is a glycoprotein containing three N-linked glycosylation sites in the ECD (Jin 
et al., 2007). Although some TLR crystal structures have been solved with attached 
glycan chains (Bell et al., 2005; Jin et al., 2007), this may not be possible in all cases as 
the crystal packing and associated crystal contacts may require their removal. The 
heterogeneity and flexibility introduced by glycosylation is known to cause problems 
during crystallization (Baker et al., 1994). Therefore, several strategies to optimize the 
glycosylation state of the protein were derived. In addition to insect cell production, 
which reduces glycosylation compared to most eukaryotic cell lines, mTLR2 was 
produced in CHO lec3.2.8.1 glycosylation mutant cells, a cell line developed to produce 
glycoproteins with dramatically simplified surface carbohydrates (Stanley, 1989; Wilke 
et al., 2010). Sf21 insect cells by contrast give rise to significantly more complex 
glycoproteins (Kulakosky et al., 1998). Expression in CHO lec3.2.8.1 cells is expected 
to result in a homogenous Man5 oligomannosyl form linked to the two proximal N-
acetylglucosamines (GlcNAc) (Stanley, 1989). 
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Figure  IVA-7 N-glycosylation of CHO lec3.2.8.1 
The two proximal N-Acetylglucosamine (GlcNAc) units are linked to 5 mannose (Man) moieties. The 
arrow indicates the PNGase F cleavage site between the innermost GlcNAc and the asparagine residue. 
 
Apart from the cell line, the degree of glycosylation also depends on the protein-specific 
accessibility during processing. This can thus result in micro-heterogeneity in the target 
protein. 
We exposed mTLR2 to PNGase F prior to crystallization. PNGase F is an amidase that 
cleaves the link between the glycosylated asparagine and the first GlcNAc in N-linked 
glycoproteins (Tarentino et al., 1985) (Figure  IVA-7). The outcome of this treatment 
could be verified by SDS-PAGE only for glycosylated TLR2 produced in Sf21 insect 
cells due to the large size of the glycosylation structures (see Figure  IIIA-4). For CHO 
lec3.2.8.1 cells, the size of the sugar moiety amounts to a mere 1.34 kDa (5x Man + 2x 
GlcNAc) and is below the resolution limit for SDS-PAGE. However, the cleavage 
conditions established for mTLR2 from Sf21 were similarly used for CHO cell 
produced protein. Overall deglycosylation of mTLR2 reduces the heterogeneity and 
entropy associated with oligosaccharide chain flexibility. 
In the course of this thesis, mTLR2 was purified using a non-cleavable, C-terminal 
His6-tag. As His6-tags are assumed to be largely unstructured and flexible they may 
potentially interfere with contacts required for the growth of protein crystals. A 
recommendation is therefore to remove the tag by cleavage after purification (Carson et 
al., 2007). In fact, to date more than 11500 proteins have been successfully crystallized 
and their structures solved (statistic from www.pdb.org) despite the presence of a C- or 
N-terminal His6 (or longer) tag. In the context of TLR2/OPN-305 Fab crystallization 
removing of the tag may be a reasonable step in overcoming the crystallization 
problems described and to improve crystal quality. For this, the gene construct would 
need to be recloned to add a protease cleavage site between TLR2 and the His6-tag. 
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TEV protease is a commonly used enzyme for protein cleavage and shows a high 
specificity and activity. 
 
IVA.3.2 Alternative crystallization strategies  
Although a variety of approaches and strategies were employed to produce well 
diffracting TLR2/Fab crystals, a maximal diffraction of only 8 Å could be achieved. 
The diffraction data nevertheless permitted unit cell parameters and the space group to 
be determined: space group C222 with unit cell dimensions of a = 176 Å, b = 310 Å, 
and c = 97 Å. The diffraction pattern revealed moderate anisotropy resulting in a higher 
diffraction limit in the vertical as compared to the horizontal direction (see Figure 
 IIIA-25). One very long unit cell axis (b = 310 Å) may contribute to the anisotropy, as 
the unit cells need to retain the proper packing over three times the distance in this 
direction compared to c in order to reach the same resolution. Alternatively, diffraction 
anisotropy may indicate crystal packing interactions to be more uniform in one direction 
than another. Crystal contacts might be more easily formed on one side of the complex 
molecule than on another. The improvements of purification pointed out above could 
help to increase crystal contacts and packing. 
Further efforts to improve crystal quality would be an even more extensive sampling of 
crystallization conditions including more temperatures, starting conditions, protein 
concentrations or additives. There is evidence that microseed matrix screening is a 
promising approach to crystallize antibody-antigen complexes, in which seeds are 
systematically transferred into new conditions to promote crystal growth (Obmolova et 
al., 2010). It is based on the concept that the conditions that are best for crystal growth 
may be different from those that favor nucleation. Therefore it is reasonable to increase 
efforts in finding new crystallization conditions. 
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IVB Establishing TLR2 / TLR6 production in eukaryotic cells 
As an increasing number ligands are being identified for TLR2 and its partners TLR1 
and TLR6, their complexes will remain a focus of structural analysis. Although crystal 
structures for TLR2/TLR1 and TLR/TLR6 in complex with lipopeptides have been 
solved, the epitopes of other TLR2 ligands such as LTA, PGN or Zymosan still remain 
to be identified. Several adaptor proteins are known to be involved in dimerization 
and/or ligand binding. For example, CD36 is believed to be required for full signaling 
efficacy through TLR2/TLR6 in complex with LTA or the lipopeptide MALP-2 
(Beutler et al., 2006). In addition, potential agonists and antagonists can be structurally 
analyzed in complex with TLRs. For this purpose the production of mouse/human 
TLR2 and TLR6 in insect cells using the baculovirus expression system may be of 
continued interest. Suggestions with respect to their improved production and 
purification ability are discussed below. 
 
IVB.1 Insect cell production of mouse/human TLR2 and TLR6 
As outlined above, we successfully generated DNA constructs, baculoviral DNA and 
produced sufficient baculovirus for murine and human TLR2 and TLR6 extracellular 
domains. However, protein production was only partly successful. In particular the 
expression of mouse/human TLR6 was significantly weaker or completely absent 
(hTLR6) compared to that of mouse/human TLR2 (see Figure  IIIB-5). One reason may 
involve the number of glycosylation sites as hTLR6 (9 N-glycans) and mTLR6 (10 N-
glycans) have twice to three times the number of hTLR2 (4 N-glycans) and mTLR2 (3 
N-glycans). Complex glycosylation can reduce protein production in insect cells leading 
to less soluble and less stable protein. Interestingly the crystal structure of the 
TLR2/TLR6 complex was solved using the murine proteins (Kang et al., 2009), despite 
the complex of human TLR2/TLR1 having been solved before (Jin et al., 2007). 
Possibly, the authors of that study encountered similar difficulties in producing hTLR6 
as described above. 
The protein secretion rate in this study was lower than expected resulting in a large 
fraction of the protein being diverted to intracellular inclusion bodies (see Figure 
 IIIB-6). Additional attempts at using other signal peptides or other cell lines could be 
undertaken to identify conditions yielding higher protein solubility and more efficient 
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secretion rates. Alternatively, instead of utilizing secreted protein, the soluble 
intracellular fraction could also be isolated and tested for folded protein. Our own 
efforts to refold protein solubilized from inclusion bodies were not successful (data not 
shown).  
 
IVB.2 Purification of produced TLR2 and TLR6 
The yield of protein in eukaryotic cells in general and of TLR2 in particular is rather 
low (Results,  IIIA.1.1) providing a mere 500 µg per L after affinity chromatography. 
The number of purification steps is known to be proportional to the rate of protein loss. 
However, screening for crystallization conditions and optimization of crystals usually 
requires significantly higher amounts of protein. Protein expression therefore developed 
into one of the bottlenecks for this project and had major cost and infrastructure 
implications. We originally designed novel recombinant proteins that would have 
allowed their purification in a single affinity chromatography step by making use of the 
high affinity between the C-terminal Fc-tag and Protein A matrix. As the Fc-tagged 
proteins cannot be eluted easily from Protein A columns, a TEV protease cleavage site 
was inserted between tag and protein to allow for its facile release. 
mTLR2 and hTLR2 were produced in the derived system, while evidence for weak 
expression of mTLR6 was obtained by SDS-PAGE. The single bands in SDS-PAGE 
analysis confirmed the excellent purification efficiency (see Figure  IIIB-7). However, 
the TEV protease cleavage site between the protein and the Fc-tag proved inaccessible 
to the protease possibly due to steric hindrance preventing the release of the TLR-ECD 
proteins (see Figure  IIIB-8, Figure  IIIB-9). Elution of the immobilized protein by pH 
shift for digestion in solution denatured the protein and hence did not provide an 
alternative route. A new construct was therefore designed that incorporates a five amino 
acid spacer between the TEV protease cleavage site and the Fc-tag to facilitate the 
protease interaction (see Figure  IIIB-11). The insertion into the original construct by 
quick change mutagenesis was successful. Alternatively, the Fc-tag was removed by 
inserting a stop codon by quick change mutagenesis to test whether the Fc-tag itself 
negatively affects protein secretion (see Figure  IIIB-10). Due to time constraints the 
new construct were not used during this thesis. They, nevertheless, provide a good 
starting point for continuing the project by other researchers. 
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V Outlook 
 
VA.1 Inhibition of TLR2 with a monoclonal antibody 
The described structural results for TLR2 in complex with an antagonistic antibody 
represent the first insights into a mechanism of TLR2 inhibition with a potential 
therapeutic drug. The identification of the OPN-305 epitope on TLR2 together with its 
surface residues in this thesis is the basis for a new patent application from Opsona to 
isolate epitope fragments or to construct template molecules onto which chemical 
groups which mimic the epitope are grafted having the specified residues and structure 
coordinates and to facilitate the generation or identification of new binding members 
having the same or similar functional properties as OPN-305. It may be possible to use 
the hybrid LRR technique for the development of a scaffold for epitope grafting or to 
stabilize and/or modify shorter epitope-containing fragments of TLR2 without 
compromising their structural integrity (Jin and Lee, 2008a).  It would be further 
interesting to substitute an array of epitope surface residues identified in this work to 
verify their contribution on antibody interaction. Different combinations of single 
mutations should be performed and the influence of the TLR2 mutants on OPN-305 
binding could be well characterized with techniques such as flow cytometry by using a 
fluorescent-labeled antibody. By solving the crystal structure of TLR2/OPN-305 the 
exact structure coordinates of the epitope residues could be determined and possible 
deviations from the available TLR2 crystal structures could be declared. LRR10 and 
LRR11 appear in two conformations dependent if TLR2 is a monomer or not. 
Crystallization analysis could reveal the orientation of these loops in the antibody-
bound state. Further analysis of the cross-reactivity property of OPN-305 was 
performed in this work by multi-sequence alignment of the identified epitope with 
TLR2 from other mammals. Based on the sequence consensus it revealed that OPN-305 
is likely to inhibit TLR2 of most of mammalian classes. This analysis leads to a possible 
additional application of the antibody for the treatment of domestic and farm animals 
like dogs, horses, cattle and sheep, for example in septic shock pathology. Dogs are 
known to suffer from canine rheumatoid arthritis (CRA) and SLE-related diseases 
correlating with increased cytokine expression (Carter et al., 1999; Hegemann et al., 
2003; Wilbe et al., 2009). Thus, the cross-reactivity of OPN-305 is not only a beneficial 
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feature to study the effectiveness of the antibody in animal models prior to human 
treatment, but also a promising attribute to treat diverse disease patterns in animals. 
Therefore, more binding studies with TLR2 from other origins should be carried out to 
eventually extend the application range of OPN-305. 
 
 
VA.2 Producing mouse/human Toll-like receptors 2 and 6 in insect 
cells using the baculovirus expression system 
Efficient production of TLRs in a eukaryotic expression system is a prerequisite for 
structural analysis. Replacing the secretion signal and the utilization of very specific 
purification tags are strategies that could improve overall protein yield. In this work we 
could show that using an Fc-tag for purification results in a very high purity as 
expected. However, the fusion tag could not be cleaved following purification, but 
efforts have been started to modify the current protein constructs by insertion of a 
spacer between cleavage site and fusion tag. Future experiments should concentrate on 
the establishing of the production of the new modified proteins in the baculovirus 
expression system. To determine the efficiency of the chosen signal peptide gp67, it 
might be reasonable to additionally test the native signal peptides of the respective 
proteins. CHO cells - a mammalian cell line and thus evolutionary more close to 
humans and mice - could be tested for protein expression instead of insect cells to 
improve overall protein quality. TLR2 and TLR6 remain in the focus of interest for 
crystallography for structural analysis on the interaction of TLR2/TLR6 with LTA or 
MALP-2 and in complex with adaptor proteins such as CD36. 
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